bvs-20260422

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐Preliminary Proxy Statement

☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐Definitive Additional Materials

☐Soliciting Material under §240.14a-12

Bioventus Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒No fee required

☐Fee paid previously with preliminary materials

☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Table of Contents

NOTICE & PROXY STATEMENT Annual Meeting of Stockholders

June 3, 2026

10:00 a.m. (Eastern Time)

Meeting to be held virtually

BIOVENTUS INC.

4721 EMPEROR BOULEVARD, STE. 100

DURHAM, NORTH CAROLINA 27703

Table of Contents


Dear Fellow Stakeholders:


			“We are encouraged by our momentum, confident in our strategy, and excited about the growth opportunities ahead.” ROBERT E. CLAYPOOLE, President, Chief Executive Officer and Director


April 22, 2026
Dear Fellow Stakeholders:
2025 was another strong year for Bioventus, marked by continued execution against our strategy and tangible progress toward our long term growth objectives. We delivered results in line with—or ahead of—our expectations, reflecting disciplined operational execution, improved commercial performance, and ongoing portfolio optimization. Notably, this represents the third consecutive year in which we met or exceeded our financial guidance, and I am proud of the efforts of the entire Bioventus team for reinforcing the credibility of our company’s operating model. Our results reflect the benefits of a more focused organization and improved execution across sales, operations, and cost management. The actions we have taken over the past several years have strengthened our foundation and increased our confidence in our ability to scale efficiently to meet growing demand. As a result, we believe Bioventus is entering an increasingly attractive phase of its evolution. For example, in 2025, we made important progress advancing our future growth drivers. Pilot launches of our Peripheral Nerve Stimulation products for chronic pain and our Platelet Rich Plasma product generated encouraging early market feedback and provided valuable insights to inform broader commercialization. These initiatives, alongside our established market leading products in our core businesses, support a growth trajectory that we believe can deliver consistent performance across economic cycles. Moving forward, our focus will be on accelerating top line growth while expanding profitability, driven by targeted investments in higher growth areas of our portfolio, improved mix, and strong operating leverage. These priorities will position us to reinvest in innovation, strengthen our balance sheet, and enhance long term shareholder returns.						On behalf of our Board of Directors, I am pleased to invite you to attend the 2026 Annual Meeting of Stockholders of Bioventus Inc., to be held virtually on Wednesday, June 3, 2026, at 10:00 a.m. Eastern Time. We value your engagement and encourage you to vote your shares in advance of the Annual Meeting, regardless of whether you plan to attend. Information regarding the matters to be voted on is included in the accompanying Notice of Annual Meeting of Stockholders and proxy statement. Thank you for your continued support and investment in Bioventus. We are encouraged by our momentum, confident in our strategy, and excited about the growth opportunities ahead. As we move into 2026 and beyond, we remain focused on executing our plan, driving sustainable growth and profitability, and creating long term value for our stockholders as we continue to help patients recover and lead active lives. Sincerely, Robert E. Claypoole President, Chief Executive Officer and Director


Table of Contents


Proxy Statement	3	Committees of the Board	26
Proposals	3	Audit and Risk Committee	26
Recommendations of the Board	3	Compensation Committee	27
		Compliance, Ethics and Culture Committee	27
Information about this Proxy Statement	4	Nominating and Corporate Governance Committee	28

Questions and Answers about the 202 6 Annual Meeting of Stockholders	6	Executive and Director Compensation	28
		202 5 Summary Compensation Table	28
		Narrative to Summary Compensation Table	29
Proposals to be Voted on	10	Outstanding Equity Awards at 202 5 Fiscal Year End	32
Proposal 1: Election of Directors	10
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm	18	Director Compensation	33


		S ecurity Ownership of Certain Beneficial Owners and Managemen t	34
Equity Compensation Plan Information	19
Report of the Audit and Risk Committee of the Board of Directors	20
		Certain Relationships and Related Person Transactions	37

Independent Registered Public Accounting Firm Fees and Other Matters	21
		Stockholders' Proposals	43
		Delinquent Section 16(a) Reports	43
Executive Officers	21	Compensation Committee Interlocks and Insider Participation	43

Corporate Governance	22
General	22	Other Matters	44
Board Composition	22
Director Independence	23	Solicitation of Proxies	44
Director Candidates	23
Communications from Stockholders	24	Bioventus's Annual Report on Form 10-K	45
Board Leadership Structure and Role in Risk Oversight	24

Code of Compliance and Ethics	25
Anti-Hedging Policy and Insider Trading and Compliance Policy	25

Compensation Recovery Policy	25
Attendance by Members of the Board of Directors at Meetings	25

Table of Contents


Notice of Annual Meeting of Stockholders

The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Bioventus Inc. (the "Company") will be held as follows:

Items of Business

To elect the twelve (12) directors nominated by the Board of Directors to serve until the 2027 Annual Meeting (the "2027 Annual Meeting") and until their respective successors have been duly elected and qualified; and

Wednesday, June 3, 2026

To ratify the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and

10:00 a.m. Eastern Time

To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.

The Annual Meeting will be a virtual meeting of stockholders to be held as a live webcast over the Internet at:

www.virtualshareholdermeeting.com/BVS2026

April 6, 2026

Holders of our Class A and Class B common stock at the close of business on the record date are entitled to receive notice of, and to vote at, the Annual Meeting, or any postponement or adjournment thereof.

The list of these stockholders will also be available on the bottom of your screen during the Annual Meeting after entering the 16-digit control number included on your Notice of Internet Availability of Proxy Materials (the "Internet Notice"), on your proxy card or on the instructions that accompanied your proxy materials. The Annual Meeting may be postponed or adjourned from time to time without notice other than by announcement at the Annual Meeting.

Proxy Voting

Your vote is important. We encourage you to mark, date, sign and return the enclosed proxy/voting instruction card or, if you prefer, to vote by telephone or by using the Internet.

April 22, 2026

By Order of the Board of Directors

Anthony D’Adamio

Senior Vice President, General Counsel and Secretary

Durham, North Carolina


It is important that your shares be represented regardless of the number of shares you may hold. Whether or not you plan to attend the Annual Meeting online, we urge you to vote your shares via the toll-free telephone number or over the Internet, as described in the enclosed materials. If you received a copy of the proxy card by mail, you may sign, date and mail the proxy card in the enclosed return envelope. Promptly voting your shares is important to ensure the presence of a quorum at the Annual Meeting and will save the Company the expense of further solicitation. Submitting your proxy now will not prevent you from voting your shares at the Annual Meeting if you desire to do so, as your proxy is revocable at your option.

BIOVENTUS • 2026 Proxy Statement 1

Table of Contents

Proxy Summary

This summary highlights information contained elsewhere in this proxy statement. This summary does not contain all the information that you should consider, and you should read the entire proxy statement carefully before voting. Page references are supplied to help you find further information in this proxy statement.

Annual Meeting Stockholders

DATE & TIME

RECORD DATE

VOTING

10:00 a.m., Eastern Time on

April 6, 2026

Holders of our Class A common stock and Class B common stock as of the Record Date are entitled to vote. Each share of Class A common stock and Class B common stock is entitled to one vote for each of the proposals to be voted on.

June 3, 2026

MAILING DATE

This proxy statement will be first mailed or made available to stockholders on the Internet on or about April 22, 2026.

VIRTUAL MEETING

www.virtualshareholdermeeting.com/BVS2026

A complete list of holders of record of our Class A common stock and Class B common stock will be open to the examination of any stockholder for a period of ten days prior to the Annual Meeting at our principal executive offices at 4721 Emperor Boulevard, Ste. 100, Durham, North Carolina 27703. The list of these stockholders will also be available on the bottom of your screen during the Annual Meeting after entering the 16-digit control number included on your Internet Notice, on your proxy card or on the instructions that accompanied your proxy materials. The Annual Meeting may be postponed or adjourned from time to time without notice other than by announcement at the Annual Meeting.

Voting Matters and Vote Recommendation (pages 3 and 4)

The following table summarizes the proposals to be considered at the Annual Meeting and the Board of Directors' (the "Board") voting recommendation with respect to each proposal.


Proposals			Board Vote Recommendation
Election of the twelve (12) directors nominated by the Board to serve until the 2027 Annual Meeting and until their respective successors have been duly elected and qualified.			FOR
Ratification of Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.			FOR

How to Cast Your Vote (page 7)

You can cast your votes by any of the following methods:

INTERNET

TELEPHONE

MAIL

(www.proxyvote.com)

(1-800-690-6903)

Completing, signing and returning your proxy

card or voting instruction card so that it is

received by the close of business on Tuesday, June 2, 2026

until 11:59 p.m., Eastern Time on Tuesday, June 2, 2026

until 11:59 p.m., Eastern Time on Tuesday,

June 2, 2026


			Whether you are a stockholder of record or hold your shares in “street name,” you may participate in and vote online at the Annual Meeting. You will need to enter your 16-digit control number (included in your Internet Notice, your proxy card or the voting instructions that accompanied your proxy materials) to vote your shares at the Annual Meeting. Instructions on how to attend the Annual Meeting live over the Internet, and how to vote your shares during the Annual Meeting, are posted at www.virtualshareholdermeeting.com/BVS2026.

BIOVENTUS • 2026 Proxy Statement 2

Table of Contents

Proxy Statement

This proxy statement is furnished in connection with the solicitation by the Board of proxies to be voted at the Annual Meeting to be held on Wednesday, June 3, 2026 at 10:00 a.m., Eastern Time, and at any postponement or adjournment thereof. The Annual Meeting will be a completely virtual meeting, conducted via live webcast. You will be able to attend the Annual Meeting online and submit your questions and vote during the meeting by visiting www.virtualshareholdermeeting.com/BVS2026 and entering your 16-digit control number included in your Internet Notice, on your proxy card or on the instructions that accompanied your proxy materials.

Holders of record of shares of our Class A common stock, $0.001 par value per share (“Class A common stock”), and Class B common stock, $0.001 par value per share (“Class B common stock” and, together with our Class A common stock, the “Common Stock”), as of the close of business on April 6, 2026 (the “Record Date”), will be entitled to notice of and to vote at the Annual Meeting and any postponement or adjournment thereof. As of the Record Date, there were 67,638,295 shares of Class A common stock and 15,786,737 of Class B common stock outstanding and entitled to vote at the Annual Meeting, representing 81.1% and 18.9% of the combined voting power of our Common Stock, respectively. Each share of Common Stock is entitled to one vote on any matter presented to stockholders at the Annual Meeting.

This proxy statement and the Company’s Annual Report to Stockholders for the year ended December 31, 2025 (the “2025 Annual Report”) will be released on or about April 22, 2026 to our stockholders as of the Record Date.

In this proxy statement, “Bioventus”, “Company”, “we”, “us”, and “our” refer to Bioventus Inc.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD JUNE 3, 2026.

This proxy statement and our 2025 Annual Report are available at http://www.proxyvote.com/. To view these materials please have your 16-digit control number(s) available that is included in your Internet Notice, on your proxy card or on the instructions that accompanied your proxy materials. On this website, you can also elect to receive distributions of our proxy statements and annual reports to stockholders for future annual meetings of stockholders by electronic delivery. For specific instructions on making such an election, please refer to the instructions on your proxy card or voting instruction form.

Proposals

At the Annual Meeting, our stockholders will be asked:

•Proposal 1: To elect the twelve (12) directors nominated by the Board to serve until the 2027 Annual Meeting and until their respective successors have been duly elected and qualified;

•Proposal 2: To ratify the appointment of Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and

•To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.

We know of no other business that will be presented at the Annual Meeting. If any other matter properly comes before the stockholders for a vote at the Annual Meeting, however, the proxy holders named on the Company’s proxy card will vote your shares in accordance with their best judgment.

Recommendations of the Board of Directors

The Board recommends that you vote your shares as indicated below. If you return a properly completed proxy card, or vote your shares by telephone or Internet, your shares of Common Stock will be voted on your behalf as you direct. You may also vote your shares online at the Annual Meeting. If not otherwise specified, the shares of Common Stock represented by the proxies will be voted, and the Board recommends that you vote:

•FOR Proposal 1: The election of the twelve (12) directors nominated by the Board to serve until the 2027 Annual Meeting and until their respective successors have been duly elected and qualified; and

•FOR Proposal 2: The ratification of the appointment of Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

If any other matter properly comes before the stockholders for a vote at the Annual Meeting, the proxy holders named on the Company’s proxy card will vote your shares in accordance with their best judgment.

BIOVENTUS • 2026 Proxy Statement 3

Table of Contents

Information About this Proxy Statement

Why you received this proxy statement. You are viewing or have received these proxy materials because the Board is soliciting your proxy to vote your shares at the Annual Meeting. This proxy statement includes information that we are required to provide to you under the rules of the Securities and Exchange Commission (“SEC”) and that is designed to assist you in voting your Company shares.

Notice of Internet Availability of Proxy Materials.

As permitted by SEC rules, Bioventus is making this proxy statement and its 2025 Annual Report available to its stockholders electronically via the Internet. On or about April 22, 2026, we will mail to our stockholders an Internet Notice containing instructions on how to access this proxy statement and our 2025 Annual Report and vote online. If you received an Internet Notice by mail, you will not receive a printed copy of the proxy materials in the mail unless you specifically request them. Instead, the Internet Notice instructs you on how to access and review all of the important information contained in the proxy statement and 2025 Annual Report. The Internet Notice also instructs you on how you may submit your proxy over the Internet. If you received an Internet Notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting such materials contained on the Internet Notice.

Printed Copies of Our Proxy Materials. If you received printed copies of our proxy materials, then instructions regarding how you can vote are contained on the proxy card included in the materials.

Householding. SEC rules permit us to deliver a single set of proxy materials to one address shared by two or more of our stockholders. This delivery method is referred to as “householding” and can result in significant cost savings. To take advantage of this opportunity, we have delivered only one set of proxy materials to multiple stockholders who share an address, unless we received contrary instructions from the impacted stockholders prior to the mailing date. We agree to deliver promptly, upon written or oral request, a separate copy of the proxy materials, as requested, to any stockholder at the shared address to which a single copy of those documents was delivered.

If your household received a single set of proxy materials this year, but you would prefer to receive your own copy, please contact Broadridge Householding Department, by calling their toll free number, 1-866-540-7095 or by writing to: Broadridge, Householding Department, 51 Mercedes Way, Edgewood, New York 11717. You will be removed from the householding program within 30 days of receipt of your instructions at which time you will then be sent separate copies of the documents. If you are currently a stockholder sharing an address with another stockholder and wish to receive only one copy of future proxy materials for your household, please contact Broadridge at the above phone number or address.

BIOVENTUS • 2026 Proxy Statement 4

Table of Contents

Forward-Looking Statements.

This proxy statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this proxy statement that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning Bioventus’s future financial results and liquidity; our business strategy, position and operations; and expected sales trends, opportunities, market position and growth. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this proxy statement include, but are not limited to, the risks related to unexpected increases in the volume of rebate claims; the risks related to tariffs and unexpected changes in tariffs, trade barriers and regulatory requirements, export licensing requirements or other restrictive actions by the United States or retaliatory tariffs and other actions taken by foreign governments; the FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing our products; if we fail to properly manage growth or scale our business processes, systems, or data management, our business could suffer; our ability to maintain our competitive position depends on our ability to attract, retain and motivate our senior management team and highly qualified personnel necessary to execute our strategic plans; demand for our products could decrease as a result of healthcare cost-containment and drug pricing initiatives by the federal government, which could negatively impact the commercial success of affected products; we may face issues with respect to the supply of our products or their components due to product quality and regulatory compliance issues, including increased costs, disruptions of supply, shortages, contamination or mislabeling; we might not meet certain of our debt covenants under our 2025 Credit Agreement and might be required to repay our indebtedness on an accelerated basis; there are restrictions on operations and other costs associated with our indebtedness; we might require additional capital to fund our current financial obligations and support business growth; failure to establish and maintain effective financial controls could adversely affect our business and stock price; our cash is maintained at financial institutions, often in balance that exceed federally insured limits; we have been subject to securities class action litigation and currently have pending derivative shareholder lawsuits and may be subject to similar or other litigation in the future, which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes; risks related to product liability claims; our reliance on a limited number of third-party manufacturers to manufacture certain of our products; if our facilities are damaged or become inoperable, we will be unable to continue to research, develop and manufacture certain of our products; economic, political, regulatory and other risks related to international sales, manufacturing and operations; failure to maintain contractual relationships; security breaches, unauthorized access to or disclosure of information, cyberattacks, or other incidents or the perception that confidential information in our or our vendors’ or service providers’ possession or control is not secure; failure of key information technology and communications systems, process or sites; risks related to our future capital needs; economic, political (including international tariffs), regulatory and other risks related to international sales, manufacturing and operations; unstable political or economic conditions; failure to maintain contractual relationships; failure to comply with extensive governmental regulation relevant to us and our products; legislative or regulatory reforms; risks related to intellectual property matters; the dilution of our Class A common stockholders upon an exchange of the outstanding common membership interests in Bioventus LLC could adversely affect the market price of our Class A common stock and the resale of such shares could cause the market price of our Class A common stock to fall; and the other risks identified in the Risk Factors section of the Company’s public filings with the SEC, including Bioventus’s Annual Report on Form 10-K for the year ended December 31, 2025, and as such factors may be further updated from time to time in Bioventus’s other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’s website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

BIOVENTUS • 2026 Proxy Statement 5

Table of Contents

Questions and Answers about the 2026 Annual Meeting of Stockholders

Who is entitled to vote at the Annual Meeting?

The Record Date for the Annual Meeting is April 6, 2026. You are entitled to vote at the Annual Meeting only if you were a holder of record of Common Stock at the close of business on that date, or if you hold a valid proxy for the Annual Meeting. Each outstanding share of Common Stock is entitled to one vote for all matters before the Annual Meeting. At the close of business on the Record Date, there were 67,638,295 shares of Class A common stock and 15,786,737 shares of Class B common stock outstanding and entitled to vote at the Annual Meeting.

What is the difference between being a “record holder” and holding shares in “street name”?

A record holder holds shares in his or her name. If you are a record holder, your set of proxy materials has been sent to you directly by the Company.

Shares held in “street name” means shares that are held in the name of a bank or broker on a person’s behalf. Proxy materials have been forwarded to you by that organization if your shares are held in “street name.”

Am I entitled to vote if my shares are held in “street name”?

Yes. If your shares are held by a bank or a brokerage firm, you are considered the “beneficial owner” of those shares held in “street name.” If your shares are held in street name, these proxy materials are being provided to you by your bank or brokerage firm, along with a voting instruction card if you received printed copies of the proxy materials. As the beneficial owner, you have the right to direct your bank or brokerage firm how to vote your shares, and the bank or brokerage firm is required to vote your shares in accordance with your instructions. If your shares are held in street name and you would like to vote at the Annual Meeting, you may visit www.virtualshareholdermeeting.com/BVS2026 and enter the 16-digit control number included in the voting instruction card provided to you by your bank or brokerage firm. If you hold your shares in street name and you did not receive a 16-digit control number, you may need to log in to your bank or brokerage firm’s website to access the meeting and vote. Instructions should also be provided on the voting instruction card provided by your bank or brokerage firm.

How many shares must be present to hold the Annual Meeting?

A quorum must be present at the Annual Meeting for any business to be conducted. The presence at the Annual Meeting online or by proxy, of the holders of a majority in voting power of the Common Stock issued and outstanding and entitled to vote on the Record Date will constitute a quorum.

Who can attend the Annual Meeting?

Bioventus has decided to hold the Annual Meeting entirely online this year. You may attend the Annual Meeting online only if you are a Bioventus stockholder who is entitled to vote at the Annual Meeting, or if you hold a valid proxy for the Annual Meeting. You may attend and participate in the Annual Meeting by visiting the following website: www.virtualshareholdermeeting.com/BVS2026. To attend and participate in the Annual Meeting, you will need the 16-digit control number included in your Internet Notice, on your proxy card or on the instructions that accompanied your proxy materials. If your shares are held in “street name,” you may visit www.virtualshareholdermeeting.com/BVS2026 and enter the 16-digit control number included in the voting instruction card provided to you by your bank or brokerage firm. If you hold your shares in street name and you did not receive a 16-digit control number, you may need to log in to your bank or brokerage firm’s website to access the meeting and vote. Instructions should also be provided on the voting instruction card provided by your bank or brokerage firm.

The meeting webcast will begin promptly at 10:00 a.m., Eastern Time. We encourage you to access the meeting prior to the start time. Online check-in will begin at 9:45 a.m., Eastern Time, and you should allow ample time to complete the check-in procedures.

What if a quorum is not present at the Annual Meeting?

If a quorum is not present at the scheduled time of the Annual Meeting, either (i) the person presiding over the meeting or (ii) if directed to be voted on by the person presiding over the meeting, a majority in voting power of the stockholders entitled to vote at the meeting, present electronically or represented by proxy, shall have power to adjourn the meeting from time to time until a quorum is present or represented.

BIOVENTUS • 2026 Proxy Statement 6

Table of Contents

What does it mean if I receive more than one Internet Notice or more than one set of proxy materials?

It means that your shares are held in more than one account at the transfer agent and/or with banks or brokers. Please vote all of your shares. To ensure that all of your shares are voted, for each Internet Notice or set of proxy materials, please submit your proxy by phone, via the Internet, or, if you received printed copies of the proxy materials, by signing, dating and returning the enclosed proxy card in the enclosed envelope.

How do I vote?

Stockholders of Record. If you are a stockholder of record, you may vote:

•by Internet—you can vote over the Internet at www.proxyvote.com by following the instructions on the Internet Notice or proxy card;

•by telephone—you can vote by telephone by calling 1-800-690-6903 and following the instructions on the proxy card;

•by mail—you can vote by mail by signing, dating and mailing the proxy card, which you may have received by mail; or

•by voting online during the Annual Meeting—you can vote during the Annual Meeting by going to www.virtualshareholdermeeting.com/BVS2026.

Internet and telephone voting facilities for stockholders of record will be available 24 hours a day and will close at 11:59 p.m., Eastern Time, on June 2, 2026. Mailed proxy cards must be received by June 2, 2026 in order to be counted at the Annual Meeting. To participate in the Annual Meeting, including to vote via the Internet or telephone or electronically during the meeting, you will need the 16-digit control number included on your Internet Notice, on your proxy card or on the instructions that accompanied your proxy materials.

Whether or not you expect to attend the Annual Meeting online, we urge you to vote your shares as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting. If you submit your proxy, you may still decide to virtually attend the Annual Meeting and vote your shares electronically.

Beneficial Owners of Shares Held in “Street Name.” If your shares are held in “street name” through a bank or broker, you will receive instructions on how to vote from the bank or broker. You must follow their instructions in order for your shares to be voted. Internet and telephone voting also may be offered to stockholders owning shares through certain banks and brokers. If your shares are held in “street name,” you may visit www.virtualshareholdermeeting.com/BVS2026 and enter the 16-digit control number included in the voting instruction card provided to you by your bank or brokerage firm. If you hold your shares in street name and you did not receive a 16-digit control number, you may need to log in to your bank or brokerage firm’s website to access the meeting and vote. Instructions should also be provided on the voting instruction card provided by your bank or brokerage firm.

What if I lose my 16-digit control number?

If you lose your 16-digit control number, you may join the Annual Meeting as a “Guest,” but you will not be able to vote, ask questions or access the list of stockholders as of the Record Date. You will need to obtain your own Internet access if you choose to attend the Annual Meeting online and/or vote over the Internet.

Can I change my vote after I submit my proxy?

Yes. If you are a registered stockholder, you may revoke your proxy and change your vote:

•by submitting a duly executed proxy bearing a later date;

•by granting a subsequent proxy through the Internet or telephone;

•by giving written notice of revocation to the Secretary of Bioventus (the "Secretary") prior to the Annual Meeting; or

•by voting online during the Annual Meeting by going to www.virtualshareholdermeeting.com/BVS2026.

Your most recent proxy card or Internet or telephone proxy is the one that is counted. Your attendance at the Annual Meeting by itself will not revoke your proxy unless you give written notice of revocation to the Secretary before your proxy is voted or you vote online at the Annual Meeting.

If your shares are held in street name, you may change or revoke your voting instructions by following the specific directions provided to you by your bank or broker, or you may vote during the Annual Meeting by obtaining your 16-digit control number from your bank or broker or otherwise voting through your bank or broker.

BIOVENTUS • 2026 Proxy Statement 7

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING

Who will count the votes?

A representative of Broadridge Financial Solutions, Inc., our inspector of election, will tabulate and certify the votes.

What if I do not specify how my shares are to be voted?

If you submit a proxy but do not indicate any voting instructions, the persons named as proxies will vote in accordance with the recommendations of the Board. The Board's recommendations are indicated on pages 3 and 4 of this proxy statement, as well as with the description of each proposal in this proxy statement.

Do I have any dissenters’ or appraisal rights with respect to any of the matters to be voted on at the Annual Meeting?

No. Delaware law does not provide stockholders any dissenters’ or appraisal rights with respect to the matters to be voted on at the Annual Meeting.

Will any other business be conducted at the Annual Meeting?

Why hold a virtual meeting?

A virtual meeting enables increased stockholder attendance and participation because stockholders can participate from any location around the world. You will be able to attend the Annual Meeting online and submit your questions and vote by visiting www.virtualshareholdermeeting.com/BVS2026 by following the instructions above. Stockholders will have similar rights and opportunities to participate at the Annual Meeting as they would at an in-person meeting.

What if during the check-in time or during the Annual Meeting I have technical difficulties or trouble accessing the virtual meeting website?

We encourage stockholders to log into the virtual Annual Meeting beginning 15 minutes prior to the start of the Annual Meeting to test their Internet connectivity. We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting website, and the information for assistance will be located on www.virtualshareholdermeeting.com/BVS2026.

Will there be a question and answer session during the Annual Meeting?

As part of the Annual Meeting, we will hold a live Q&A session, during which we intend to answer questions submitted online during the meeting that are pertinent to the Company and the meeting matters, for up to 15 minutes following the completion of the Annual Meeting. Only stockholders that have accessed the Annual Meeting as a stockholder (rather than a “Guest”) by following the procedures outlined above in “Who can attend the Annual Meeting?” will be permitted to submit questions during the Annual Meeting. Each stockholder is limited to one question in order to allow us to answer questions from as many stockholders as possible. Questions should be succinct and only cover a single topic. We will not address questions that are, among other things:

•irrelevant to the business of the Company or to the business of the Annual Meeting;

•related to material non-public information of the Company, including the status or results of our business since our last Quarterly Report on Form 10-Q;

•related to any pending, threatened or ongoing litigation;

•related to personal grievances;

•derogatory references to individuals or that are otherwise in bad taste;

•substantially repetitious of questions already made by another stockholder;

•in excess of the question limit;

•in furtherance of the stockholder’s personal or business interests; or

•out of order or not otherwise suitable for the conduct of the Annual Meeting as determined by the Chair of the Annual Meeting or Secretary in their reasonable judgment.

BIOVENTUS • 2026 Proxy Statement 8

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING

Questions and answers may be grouped by topic, and we may group substantially similar questions together and answer them once. If there are matters of individual concern to a stockholder and not of general concern to all stockholders, or if a question posed was not otherwise answered, we encourage stockholders to contact us separately after the Annual Meeting.

Additional information regarding the Q&A session will be available in the “Rules of Conduct” available on the Annual Meeting webpage for stockholders that have accessed the Annual Meeting as a stockholder (rather than a “Guest”) by following the procedures outlined above in “Who can attend the Annual Meeting?”.

How many votes are required for the approval of the proposals to be voted upon and how will abstentions and broker non-votes be treated?


Proposal	Votes required	Effect of Votes Withheld / Abstentions and Broker Non-Votes
Proposal 1: Election of Directors.	The plurality of the votes cast. This means that the twelve nominees receiving the highest number of affirmative "For" votes will be elected as directors.	Votes withheld and broker non-votes will have no effect.
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.	The affirmative vote of the holders of a majority in voting power of the votes cast.	Abstentions and broker non-votes, if any, will have no effect. We do not expect any broker non-votes on this proposal.

What is a “vote withheld” and an “abstention” and how will votes withheld and abstentions be treated?

A “vote withheld,” in the case of Proposal 1, or an “abstention,” in the case Proposal 2, represents a stockholder’s affirmative choice to decline to vote on a proposal. Votes withheld and abstentions are counted as present and entitled to vote for purposes of determining a quorum. Because votes withheld and abstentions are not considered to be votes cast, votes withheld have no effect on Proposal 1 and abstentions have no effect on Proposal 2.

What are broker non-votes and do they count for determining a quorum?

Generally, broker non-votes occur when shares held by a broker in “street name” for a beneficial owner are not voted with respect to a particular proposal because the broker (i) has not received voting instructions from the beneficial owner and (ii) lacks discretionary voting power to vote those shares. A broker is entitled, but not obligated, to vote shares held for a beneficial owner on routine matters, such as Proposal 2 (the ratification of the appointment of Grant Thornton as the Company’s independent registered public accounting firm), without instructions from the beneficial owner of those shares. On the other hand, absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on non-routine matters, such as Proposal 1 (election of directors). Broker non-votes count for purposes of determining whether a quorum is present. Broker non-votes, if any, will have no effect on Proposal 1. We do not expect broker non-votes for Proposal 2.

Where can I find the voting results of the Annual Meeting?

We plan to announce preliminary voting results at the Annual Meeting and we will report the final results in a Current Report on Form 8-K, which we intend to file with the SEC within four business days after the Annual Meeting.

Who is paying for this proxy solicitation?

The accompanying proxy is solicited by and on behalf of our Board, whose Notice of Annual Meeting is attached to this proxy statement, and the entire cost of our solicitation will be borne by us. In addition to the use of mail, proxies may be solicited by personal interview, telephone, e-mail and facsimile by our directors, officers and other employees who will not be specially compensated for these services. We will also request that brokers, nominees, custodians and other fiduciaries forward soliciting materials to the beneficial owners of shares held by the brokers, nominees, custodians and other fiduciaries. We will reimburse these persons for their reasonable expenses in connection with these activities.

BIOVENTUS • 2026 Proxy Statement 9

Table of Contents

Proposals to be Voted on

Proposal 1: Election of Directors

At the Annual Meeting, twelve (12) directors are to be elected to hold office until the 2027 Annual Meeting and until each such director’s respective successor is elected and qualified.

From the Company's initial public offering in 2021 until this Annual Meeting, the Board had been divided into classes. At the 2024 annual meeting of stockholders, the stockholders of the Company approved an amendment to the Company's charter to phase out the classified Board structure and provide for the annual election of all directors commencing with this Annual Meeting.

In connection with the initial public offering of our Class A common stock in February 2021 (the “IPO”), we entered into a Stockholders Agreement with certain stockholders of the Company (as amended, the “Stockholders Agreement”) and our subsidiary, Bioventus LLC (“BV LLC”). Under the Stockholders Agreement, the Essex Stockholders (as defined in the Stockholders Agreement) have designated Mr. Neels, Mr. Nohra, and Mr. Sutter, and the S+N Stockholders (as defined in the Stockholders Agreement) have designated Mr. Cowdy and Dr. Dhankhar for election to the Board. As a result of the Stockholders Agreement and the aggregate voting power of the parties to the agreement, we expect that the parties to the agreement will significantly influence the election of directors. For more information, see “Certain Relationships and Related Person Transactions—Stockholders Agreement.”

In the event that any of the nominees should become unable to serve, or for good cause will not serve, as a director, it is intended that votes will be cast for a substitute nominee designated by the Board or the Board may elect to reduce its size. The Board has no reason to believe that the nominees named below will be unable to serve if elected. Each of the nominees has consented to being named in this proxy statement and to serve if elected.

Vote required

The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the twelve nominees receiving the highest number of affirmative “FOR” votes will be elected as directors. Votes withheld and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.

Recommendation of the Board of Directors

The Board unanimously recommends a vote FOR the election of the below director nominees.

BIOVENTUS • 2026 Proxy Statement 10

Table of Contents

DIRECTOR NOMINEES


Name	Age	Served as a Director Since	Positions with Bioventus
William A. Hawkins	72	2020	Chairperson
John A. Bartholdson	55	2023	Director
Patrick J. Beyer	60	2021	Director
Robert E. Claypoole	54	2024	President, Chief Executive Officer and Director
Philip G. Cowdy	59	2020	Director
Ajay Dhankhar	55	2025	Director
Mary Kay Ladone	59	2021	Director
Michelle McMurry-Heath	56	2022	Director
Guido J. Neels	77	2020	Director
Guy P. Nohra	66	2020	Director
Susan M. Stalnecker	73	2020	Director
Martin P. Sutter	71	2020	Director

The principal occupations and business experience, for at least the past five years, of each director nominee are as follows:

Age

William A. Hawkins

Professional Highlights

Director Since

William A. Hawkins has served as Chairperson and member of our Board since September 2020. Mr. Hawkins also served as chairperson of the board of managers of Bioventus LLC from January 2016 until the time of our IPO. Mr. Hawkins is a Senior Advisor to EW Healthcare Partners, a leading private equity firm investing in life sciences. From October 2011 to July 2015, Mr. Hawkins served as President and Chief Executive Officer of Immucor, Inc., a leading provider of transfusion and transplantation diagnostic products worldwide. Prior to that, Mr. Hawkins served in positions of increasing responsibility at Medtronic, Inc., a prominent medical technology company, from January 2001 to June 2011, most recently serving as its Chief Executive Officer from November 2007 to June 2011. Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation, a global leader in the field of vascular brachytherapy, from 1988 to 2002 and has also held several senior leadership positions at American Home Products (now known as Wyeth, LLC), Johnson & Johnson, Guidant Corp. and Eli Lilly and Co. Mr. Hawkins also currently serves on the board of directors of Biogen Inc. and MiMedx Group Inc., each a public biopharmaceutical company, and Baebies, Inc., Cirtec Medical Corp., Enterra Medical and Virtue Labs, LLC, each a privately-held life science company. Mr. Hawkins serves on the compensation committee and corporate governance committee of Biogen and chairs the ethics and compliance committee of MiMedx. Mr. Hawkins previously served on the board of directors of Avanos Medical, Inc. from 2015 to April 2021 and Immunor, Inc. from 2015 to 2021. Mr. Hawkins served on the Duke University Board of Trustees from 2011 to 2023, where he held the position of Vice Chair, and was appointed Duke University Trustee Emeritus in 2023. Mr. Hawkins also previously served as the Chair of the Duke University Health System board of directors. He is currently a member of the board of directors of the North Carolina Biotechnology Center and the Focused Ultrasound Foundation Society. Mr. Hawkins holds a Master of Business Administration from the University of Virginia Darden School of Business and received a Bachelor of Science in electrical and biomedical engineering from Duke University.

Other Relevant Experience

Mr. Hawkins was selected to serve on the Board because of his experience in and knowledge of the life science industry from a commercial, operational and financial perspective, including his experience as a chief executive officer of a prominent publicly traded company in the medical device industry.

2020

Committee Memberships

•Nominating and Corporate Governance

BIOVENTUS • 2026 Proxy Statement 11

Table of Contents

Age

John A. Bartholdson

Professional Highlights

Director Since

John A. Bartholdson has served as a member of our Board since January 2023. Mr. Bartholdson is the co-founder and has been a Partner of Juniper Investment Company, a private investment management firm that invests in publicly traded and private companies through concentrated ownership positions since its inception in 2007. Mr. Bartholdson has 25 years of experience leading and overseeing private and public equity investments. His experience includes extensive management oversight, service on multiple public and private company boards, and deep transactional expertise. Mr. Bartholdson presently serves as the Chairman of the board of directors of Lincoln Educational Services Corporation, a public company and a leading provider of career education and training services, and Theragenics Corporation, a private medical device company serving the surgical products and prostate cancer treatment markets. Previously, he served as a member of the board of directors of Obagi Medical Products, Inc., a public specialty pharmaceutical company, until its acquisition by Valeant Pharmaceuticals in 2013. In addition, Mr. Bartholdson has previously served on the board of directors of numerous private companies. Mr. Bartholdson was a Partner of Stonington Partners, where he worked from 1997 to 2011. Prior to that, he was an analyst at Merrill Lynch Capital Partners from 1992 to 1994. Mr. Bartholdson received his Bachelor of Arts from Duke University and his Master of Business Administration from the Stanford University Graduate School of Business.

Other Relevant Experience

Mr. Bartholdson was selected to serve on the Board because of his professional investor perspective on stockholder and related matters and his significant governance, finance, capital markets and transactional experience on multiple public and private company boards. BVS logo.jpg

2023

Committee Memberships

•Compensation (Chairperson)

•Compliance, Ethics and Culture

Age

Patrick J. Beyer

Professional Highlights

Director Since

Patrick J. Beyer has served as a member of our Board since October 2021. Mr. Beyer was appointed President and Chief Executive Officer and a member of the board of directors of ConMed Corporation, a publicly traded medical technology company, effective January 1, 2025. Prior to that, Mr. Beyer served as ConMed Corporation's Chief Operation Officer from April 2024 to December 2024, and before that as its President International and Global Orthopedics from October 2020 to April 2024. He previously served as President of ConMed International from December 2014 to October 2020. Prior to joining ConMed, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company from 2010 to 2014 when the company was sold. Prior to this, he spent 21 years at Stryker Corporation where he led Stryker Europe from 2005 to 2009; Stryker UK, South Africa and Ireland from 2002 to 2005 and Stryker Medical from 1999 to 2002. Mr. Beyer previously served on the board of directors of Misonix, Inc. from May 2021 to October 2021, where he was a member of its audit committee. Mr. Beyer graduated from Kalamazoo College with a Bachelor of Arts in Economics, Western Michigan University with a Master of Business Administration in Finance and Harvard Business School’s Advanced Management Program.

Other Relevant Experience

Mr. Beyer was selected to serve on the Board because of his extensive experience in international healthcare markets, his previous service as a chief executive officer and his broad business and public company experience.

2021

Committee Memberships

•Audit and Risk

BIOVENTUS • 2026 Proxy Statement 12

Table of Contents

Age

Robert E. Claypoole

Professional Highlights

President, Chief Executive Officer and Director Since

Robert E. Claypoole joined Bioventus in January 2024 as President and Chief Executive Officer and as a member of our Board. Mr. Claypoole joined Bioventus from Mölnlycke Health Care (“Mölnlycke”), a world-leading medical products and solutions company, where he served as Executive Vice President of Wound Care since July 2021. In this role, Mr. Claypoole had full responsibility for a $1.2 billion business. Before that, Mr. Claypoole served in several leadership positions with Mölnlycke from March 2017 to July 2021, including Executive Vice President and President, US for Mölnlycke and as an Officer of Mölnlycke Health Care US, LLC and Mölnlycke Manufacturing US, LLC. Prior to joining Mölnlycke in 2017, Mr. Claypoole served in various leadership roles at Medtronic Ltd. (now Medtronic plc (NYSE: MDT)), a global healthcare technology company, and Covidien, before it was acquired by Medtronic. Mr. Claypoole was Global Vice President & General Manager, Obesity & Metabolic Health (April 2016 to March 2017) and Global Vice President & General Manager of the Soft Tissue Repair & Hemostats business (December 2012 to April 2016). Before that, he was the Vice President, Executive Operations after serving as Vice President, Global Marketing while located in Trevoux, France. Prior to his time in France, Mr. Claypoole was the Vice President, US Marketing for the company’s Endomechanical & Intelligent Device business. Before joining Covidien in 2007, Mr. Claypoole held various marketing roles with increasing responsibility at Johnson & Johnson’s Vision Care division. Mr. Claypoole previously served on the board of directors of ZetrOz Inc. (January 2014 to January 2016) and the Association of periOperative Registered Nurses (December 2017 to December 2020). Mr. Claypoole received his Bachelor of Arts and his Master of Business Administration from Cornell University.

Other Relevant Experience

Mr. Claypoole was selected to serve on the Board because of the breadth of his experience across multiple global medical device markets and his extensive expertise in accelerating innovation, driving operational excellence, enhancing go-to-market strategies, and driving commercial execution and organizational effectiveness.

2024

Committee Memberships

N/A

Age

Philip G. Cowdy

Professional Highlights

Director Since

Philip G. Cowdy has served as a member of our Board since September 2020. Mr. Cowdy served as a member of the board of managers of BV LLC from January 2012 to October 2017 and again from July 2018 until the time of our IPO, and served as a member of its audit, compliance and quality committee. Mr. Cowdy served as the Chief Business Development and Corporate Affairs Officer for Smith & Nephew plc, a medical equipment manufacturing company, from 2018 until his retirement in May 2025. Since joining Smith & Nephew plc in June 2008, he had also served as Executive Vice President of Business Development and Corporate Affairs, Head of Corporate Affairs and Strategic Planning, Group Director of Corporate Affairs and Director of Investor Relations. Prior to joining Smith & Nephew plc, Mr. Cowdy served as a Senior Director at Deutsche Bank for 13 years, providing corporate finance and equity capital markets advice to a variety of UK-based companies. Mr. Cowdy received his Bachelor of Science in Natural Sciences from Durham University (UK) and is a qualified chartered accountant.

Other Relevant Experience

Mr. Cowdy was selected to serve on the Board because of his experience in the industry, his finance experience, and his knowledge of the Company.

2020

Committee Memberships

•Nominating and Corporate Governance

BIOVENTUS • 2026 Proxy Statement 13

Table of Contents

Age

Ajay Dhankar

Professional Highlights

Director Since

Ajay Dhankhar, PhD, has served as the Chief Corporate Development & Strategy Officer of Smith & Nephew since June 2025. Dr. Dhankhar founded Bluish Capital in July 2024, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets, and served as its Managing Partner until his appointment to Smith & Nephew. From July 2022 to June 2024, Dr. Dhankhar served as a Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd, where he was the Global Head of Medical Technology, Diagnostics and Tools. Prior to joining Lazard, Dr. Dhankhar held multiple leadership roles at McKinsey & Company over a span of 25 years, including, most recently, Senior Partner, as well as Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D. Dr. Dhankhar has a B.S. in Physics and Computer Science from Angelo State University and a PhD in Molecular Biophysics and Biochemistry from Yale University.

Dr. Dhankar was selected to serve on the Board because of his experience in the industry, and his significant finance and development experience.

2025

Committee Memberships

N/A

Age

Mary Kay Ladone

Professional Highlights

Director Since

Mary Kay Ladone has served as a member of our Board since July 2021. Ms. Ladone served as Senior Vice President, Corporate Development, Strategy and Investor Relations, of Hill-Rom Holdings, Inc. (“Hill-Rom”), a medical technology provider, from December 2018 to December 2021. Ms. Ladone previously served as Hill-Rom’s Vice President, Investor Relations, July 2016 to December 2018. Ms. Ladone served as Senior Vice President, Investor Relations, of Baxalta Inc. from 2015 to 2016 before joining Hill-Rom. Prior to Baxalta Inc., Ms. Ladone served in a variety of senior finance, business development and investor relations roles for Baxter International, Inc. Since March 2022, Ms. Ladone has also served on the board of directors of Inogen Inc., a publicly traded supplemental oxygen therapies provider, where she is a member of the audit committee and is the chair of the compensation committee. Ms. Ladone also serves on the board of directors of Kestra Medical Technologies, Inc., a publicly traded wearable medical device and digital healthcare company, where she has been the chair of the audit committee since September 2022 and a member of the nominating and corporate governance committee since March 2025, and of Novanta Inc., a publicly traded supplier of technology solutions service to medical and advanced industrial original equipment manufacturers since July 2024. Ms. Ladone holds a Bachelor of Arts in Finance and Economics from the University of Notre Dame.

Other Relevant Experience

Ms. Ladone was selected to serve on the Board due to her significant finance, investor relations, talent management and M&A experience at large healthcare companies.

2021

Committee Memberships

•Audit and Risk

•Compensation

BIOVENTUS • 2026 Proxy Statement 14

Table of Contents

Age

Michelle McMurry-Heath

Professional Highlights

Director Since

Michelle McMurry-Heath, MD, PhD, has served as a member of our Board since January 2022. Dr. McMurry-Heath served as President and Chief Operating Officer of the Biotechnology Innovation Organization, a membership and advocacy organization focused on improving biotech research and applying biotech innovations to major healthcare challenges, from 2020 to 2022. Dr. McMurry-Heath was previously with Johnson & Johnson ("J&J") from 2014 to 2020, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Prior to her time at J&J, Dr. McMurry-Heath was a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation's policies, programs and personnel. President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health where she served from 2010 to 2014. From 2005 to 2010, Dr. McMurry-Heath was Director of the Health, Biomedical Science and Society Policy Program at the Aspen Institute. Dr. McMurry-Heath began her career as a Senior Policy Advisor for Senator Joseph Lieberman for Health, Social, and Biomedical Innovation Policy from 2001 to 2004. She later served as a Robert Wood Johnson Health and Society Scholar at the University of California, San Francisco and Berkeley from 2004 to 2005 and a Macarthur Fellow, Global Health for the Council on Foreign Relations from 2004 to 2006. Dr. McMurry-Heath also serves on the board of directors at publicly traded Revvity Inc., the former life sciences and diagnostics business of the company previously known as PerkinElmer, where she is a member of the compensation committee and previously served on its audit committee. Dr. McMurry-Heath received her M.D./Ph.D. in Immunology from Duke University's Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program, and her AB in Biochemistry from Harvard University.

Other Relevant Experience

Dr. McMurry-Heath was selected to serve on the Board because of her significant policy, regulatory, commercial health-care and advocacy experience.

2022

Committee Memberships

•Compliance, Ethics and Culture (Chairperson)

BIOVENTUS • 2026 Proxy Statement 15

Table of Contents

Age

Guido J. Neels

Professional Highlights

Guido J. Neels has served as a member of our Board since September 2020. Mr. Neels served as a member of the board of managers of BV LLC from May 2012 until the time of our IPO. Mr. Neels has been with EW Healthcare Partners (formerly Essex Woodlands), a healthcare growth equity and venture capital firm, since August 2006, where he has served as Operating Partner since 2013. Prior to joining EW Healthcare Partners, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000, Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels also currently serves on the board of directors of Axogen, Inc. and is a member of its compensation committee. Mr. Neels previously served on the board of directors of Endologix, Inc. from December 2010 to June 2019 and on the board of directors of Entellus Medical from November 2009 to February 2018, each of which is a public company. Mr. Neels holds a Master in Business Administration from the Stanford University Graduate School of Business and received his Business Engineering degree from the University of Leuven in Belgium.

Other Relevant Experience

Mr. Neels was selected to serve on the Board because of his experience in the industry, familiarity with serving on the boards of public companies and his knowledge of our business.

Director Since

2020

Committee Memberships

•Compensation

Age

Guy P. Nohra

Professional Highlights

Guy P. Nohra has served as a member of our Board since September 2020. Mr. Nohra served as a member of the board of managers of BV LLC from May 2012 until the time of our IPO. In March 1996, Mr. Nohra co-founded Alta Partners, a life sciences venture capital firm, and he has since been involved in the funding and development of numerous medical technology and life sciences companies. Mr. Nohra currently serves as a member of the board of directors of Spiral Therapeutics, Inc., a private life sciences company. He also previously served on the board of directors of various public companies, including ATS Medical, Inc., Cutera, Inc., AcelRx Pharmaceuticals, Inc., and ZS Pharma, as well as several private companies, including Bionure, Inc., Sanifit Therapeutics S.A., Carbylan Biosurgery, Inc., Cerenis Therapeutics, Coapt Systems, Paracor Medical, Inc. and PneumRx. Mr. Nohra holds a Master in Business Administration from the University of Chicago and received his Bachelor of Arts in History from Stanford University.

Other Relevant Experience

Mr. Nohra was selected to serve on the Board because of his extensive experience in the life sciences industry, his investment and development experience, and his service as a director of other life sciences companies.

Director Since

2020

Committee Memberships

•Nominating and Corporate Governance

BIOVENTUS • 2026 Proxy Statement 16

Table of Contents

Age

Susan Stalnecker

Professional Highlights

Director Since

Susan M. Stalnecker has served as a member of our Board since September 2020. Ms. Stalnecker served as a member of the board of managers of BV LLC from November 2018 until the time of our IPO. Ms. Stalnecker has been a Senior Advisor at Boston Consulting Group, a global management consulting firm, since March 2016. Ms. Stalnecker served as Vice President of E.I. duPont de Nemours and Co. (now known as DuPont de Nemours, Inc., or DuPont), a diversified science and innovations public company and leader in the fields of healthcare, electronics and transportation, from December 1976 until she retired in 2016. During her nearly 40-year career at DuPont, Ms. Stalnecker served in several senior leadership roles including Vice President, Treasurer & M&A; Vice President, Risk Management; Vice President, Government and Consumer Markets; and Vice President, Productivity & Shared Services. Ms. Stalnecker also currently serves on the board of directors of Optimum Funds McQuairie, where she is a member of the audit committee. She previously served on the board of directors of Leidos Holding, Inc. from 2016 to 2025, where she was a member of the audit and finance committee. From 2009 to 2023, Ms. Stalnecker served on the Board of Trustees of the Duke Health System, where she was a member of the compliance, audit and finance committees. Ms. Stalnecker holds a Master of Business Administration from The Wharton School of the University of Pennsylvania and received her Bachelor of Arts from Duke University.

Other Relevant Experience

Ms. Stalnecker was selected to serve on the Board because of her qualifications as a financial expert and her extensive experience in treasury, governance, risk management and finance and investment management, and her service as a director of other public companies.

2020

Committee Memberships

•Audit and Risk (Chairperson)

•Compliance, Ethics and Culture

Age

Martin P. Sutter

Professional Highlights

Director Since

Martin P. Sutter has served as a member of our Board since September 2020. Mr. Sutter served as a member of the board of managers of BV LLC from May 2012 until the time of our IPO. Mr. Sutter is one of the two founding Managing Directors of EW Healthcare Partners (previously known as Essex Woodlands), one of the oldest and largest life sciences and healthcare focused growth equity and venture capital firms, which he formed in 1985. Mr. Sutter has more than 35 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter also currently serves on the board of directors of MiMedx Group, Inc., a publicly traded regenerative medicine life sciences company, and Prolacta Biosciences, Inc., a privately held life sciences company. Mr. Sutter has also previously served on the board of directors of Abiomed, Inc., Tissue Tech, Inc. and Suneva Medical, Inc. Mr. Sutter currently serves on the compensation and nominating and governance committees of MiMedx Group, Inc. and Prolacta Biosciences, Inc. and previously served on the compensation and nominating and governance committee of Abiomed, Inc. Mr. Sutter holds a Master of Business Administration from the University of Houston and received his Bachelor of Science from Louisiana State University.

Other Relevant Experience

Mr. Sutter was selected to serve on the Board because of his extensive experience in the life sciences industry, his investment experience, and his service as a director of other life sciences companies.

2020

Committee Memberships

•Nominating and Corporate Governance (Chairperson)

BIOVENTUS • 2026 Proxy Statement 17

Table of Contents

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The Audit and Risk Committee of the Board has appointed Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board has directed that this appointment be submitted to our stockholders for ratification at the Annual Meeting. Although ratification of the appointment of Grant Thornton is not required, the Company values the opinions of its stockholders and believes that stockholder ratification of the appointment is a good corporate governance practice.

Grant Thornton also served as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2025. Neither the accounting firm nor any of its members has any direct or indirect financial interest in or any connection with the Company in any capacity other than as the Company's auditors, providing audit and non-audit related services. A representative of Grant Thornton is expected to virtually attend the Annual Meeting and to have an opportunity to make a statement and be available to respond to appropriate questions from stockholders.

In the event that the appointment of Grant Thornton is not ratified by the stockholders, the Audit and Risk Committee will consider this fact when it appoints the independent auditors for subsequent fiscal years. Even if the appointment of Grant Thornton is ratified, the Audit and Risk Committee retains the discretion to appoint a different independent auditor at any time if it determines that such a change is in the best interest of the Company.

Vote Required

This proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast. Abstentions are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. Because brokers have discretionary authority to vote on the ratification of the appointment of Grant Thornton, we do not expect any broker non-votes in connection with this proposal.

Recommendation of the Board of Directors

The Board unanimously recommends a vote FOR the ratification of the appointment of Grant Thornton as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

BIOVENTUS • 2026 Proxy Statement 18

Table of Contents

EQUITY COMPENSATION PLAN INFORMATION

The following table provides, as of December 31, 2025, equity compensation plan information for all plans under which equity securities are authorized for issuance.


	Number of securities to be issued upon exercise of outstanding options and rights (a)		Weighted- average exercise price of outstanding options and rights (b)			Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected under column (a)) (4) (c)
Equity compensation plans approved by security holders (1)	6,226,186	(2)	$	8.10	(3)	13,129,209	(4)
Equity compensation plans not approved by security holders(5)	1,373,075	(6)	$	6.64	(3)	—
Total	7,599,261					13,129,209


(1)						Consists of the Bioventus Inc. 2021 Equity Incentive Plan (the "2021 Incentive Plan"), the Bioventus Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”), and the Bioventus Inc. 2023 Retention Equity Award Plan (the "2023 Retention Plan").
(2)						Includes 3,590,106 outstanding options to purchase shares of Class A common stock and 2,477,080 outstanding restricted stock units ("RSUs") under the 2021 Incentive Plan and 159,000 outstanding performance restricted stock units ("PRSUs") under the 2021 Incentive Plan.
(3)						The weighted average exercise price in column (b) does not take into account outstanding RSUs, or PRSUs, neither of which have an exercise price.
(4)						Includes 11,346,834 shares of Class A common stock available for future issuance under the 2021 Incentive Plan, 69,050 shares of Class A common stock under the 2023 Retention Plan and 1,713,325 shares of Class A common stock available for future issuance under the 2021 ESPP. The number of shares of Class A common stock reserved for issuance under the 2021 Incentive Plan automatically increases on January 1 of each calendar year from January 1, 2022 through January 1, 2031, by that number of shares of Class A common stock equal to the lesser of (i) 4.5% of the shares of Class A common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares of Class A common stock as determined by the Board. The number of shares of Class A common stock reserved for issuance under the 2021 ESPP automatically increases on January 1 of each calendar year from January 1, 2022 through January 1, 2031, by that number of shares of Class A common stock equal to the lesser of (A) 1% of the shares of Class A common stock outstanding on the last day of the immediately preceding calendar year and (B) such smaller number of shares of Class A common stock as determined by the Board.
(5)						Consists of inducement grants approved by our independent directors and made as inducements material to (i) the Senior Vice President, Chief Financial Officer, and Principal Accounting Officer of the Company and (ii) the President, Chief Executive Officer, and Principal Financial Officer of the Company entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).
(6)						Includes (i) an aggregate of 1,073,200 outstanding options to purchase shares of Class A common stock, consisting of 850,000 outstanding options held by Robert E. Claypoole and 223,200 outstanding options held by Mark Singleton, and (ii) an aggregate of 299,875 RSUs, consisting of 281,250 RSUs held by Mr. Claypoole and 18,625 RSUs held by Mr. Singleton.

BIOVENTUS • 2026 Proxy Statement 19

Table of Contents

Report of the Audit and Risk Committee of the Board of Directors

The Audit and Risk Committee has reviewed Bioventus’s audited financial statements for the fiscal year ended December 31, 2025 and has discussed these financial statements with management and Bioventus’s independent registered public accounting firm. The Audit and Risk Committee has also received from, and discussed with, Bioventus’s independent registered public accounting firm various communications that such independent registered public accounting firm is required to provide to the Audit and Risk Committee, including the matters required to be discussed by the Public Company Accounting Oversight Board (“PCAOB”) and Securities and Exchange Commission.

Bioventus’s independent registered public accounting firm also provided the Audit and Risk Committee with a formal written statement required by applicable requirements of the PCAOB describing all relationships between the independent registered public accounting firm and Bioventus, including the disclosures required by the applicable requirements of the PCAOB regarding the independent registered public accounting firm’s communications with the Audit and Risk Committee concerning independence. In addition, the Audit and Risk Committee discussed with the independent registered public accounting firm its independence from Bioventus.

Based on its discussions with management and the independent registered public accounting firm, and its review of the representations and information provided by management and the independent registered public accounting firm, the Audit and Risk Committee recommended to the Board that the audited consolidated financial statements be included in Bioventus's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Patrick J. Beyer

Mary Kay Ladone

Susan M. Stalnecker

BIOVENTUS • 2026 Proxy Statement 20

Table of Contents

Independent Registered Public Accounting Firm Fees and Other Matters

The following table summarizes fees paid or billed to us by our independent registered public accounting firm, Grant Thornton, in connection with various services for each of the last two fiscal years.


($ amounts in 000s)	2025		2024
Audit Fees(1)	$	2,247	$	1,832
Audit-Related Fees	—		—
Tax Fees	—		—
All Other Fees	—		—

(1)Audit fees are for services related to the annual audit of the Company’s consolidated financial statements, including the interim reviews of the Company’s quarterly financial statements, statutory audits of the Company’s foreign subsidiaries and consultations on accounting matters.

Pre-approval policy and procedures

The Audit and Risk Committee has adopted a policy (the “Pre-Approval Policy”) that sets forth the procedures pursuant to which audit and permissible non-audit services proposed to be provided by Grant Thornton may be pre-approved. The Pre-Approval Policy generally provides that we will not engage Grant Thornton to render any audit, audit-related, tax or other service unless the service is either (i) explicitly approved by the Audit and Risk Committee (specific pre-approval) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (general pre-approval). Unless a type of service has received general pre-approval, it will require specific pre-approval by the Audit and Risk Committee, or by a designated member of the Audit and Risk Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval.

Pre-approval fee levels or budgeted amounts for all services to be provided by Grant Thornton are established annually by the Audit and Risk Committee. Any proposed services exceeding these levels or amounts require specific pre-approval by the Audit and Risk Committee. For each fiscal year, the Audit and Risk Committee may determine the appropriate ratio between the total amount of fees for audit, audit-related and tax services, and the total amount of fees for services classified as all other services.

Other than with respect to the annual audit of the Company’s consolidated financial statements, the chairperson of the Audit and Risk Committee is delegated the authority to pre-approve other audit services and all other services. The Audit and Risk Committee monitors the performance of all services provided by Grant Thornton and determines whether such services are in compliance with this Pre-Approval Policy.

Executive Officers

The following table sets forth the name, age and position(s) of each of our executive officers as of April 22, 2026:


Name	Age	Position(s)
Robert E. Claypoole	54	President, Chief Executive Officer and Director
Mark Singleton	57	Senior Vice President and Chief Financial Officer
Anthony D’Adamio	65	Senior Vice President and General Counsel
Katrina Church	64	Senior Vice President and Chief Compliance Officer

See "Director Nominees" for information with respect to Mr. Claypoole.

BIOVENTUS • 2026 Proxy Statement 21

Table of Contents

Mark Singleton has served as the Company's Senior Vice President and Chief Financial Officer since March 2022. Mr. Singleton previously served as Vice President of Finance, Americas Strategic Business Units at Teleflex Inc. (“Teleflex”), a provider of specialty medical devices, from February 2021 to March 2022 and prior to that, served as Teleflex’s Vice President of Finance, Vascular Strategic Business Unit from 2014 to 2020. Prior to Teleflex, Mr. Singleton held multiple leadership roles at Lenovo Group Limited, a multinational technology company, including as Executive Director, Think Business Group Chief Financial Officer (2013-2014), Executive Director, Western Europe Chief Financial Officer (2011-2012), Executive Director, North America Chief Financial Officer (2007-2011) and Director, U.S. Finance Manager (2005-2007). Mr. Singleton received his Bachelor of Science from Purdue University and his Master of Business Administration from Duke University, Fuqua School of Business.

Anthony D’Adamio has served as the Company's Senior Vice President and General Counsel since August 2017. Previously, Mr. D’Adamio was General Counsel and Secretary at Siemens Healthcare (now known as Siemens Healthineers AG) from January 2010 to August 2017 and served as Deputy General Counsel and Secretary of Siemens Healthcare Diagnostics from January 2007 to January 2010. Prior to that, Mr. D’Adamio was Senior Counsel within the Diagnostics Division of Bayer Healthcare LLC (now known as Siemens Healthineers Diagnostics) from January 2001 to December 2006. Mr. D’Adamio began his legal career at the law firm of Bond, Schoeneck & King before taking corporate legal positions with companies within the health insurance, pharmaceutical and biotechnology industries, including Group Health Incorporated, Quest Diagnostics and Covance Inc. Mr. D’Adamio holds a Juris Doctor from Howard University School of Law and a Bachelor of Arts from the State University of New York at Binghamton.

Katrina Church has served as the Company's Chief Compliance Officer since August 2020. Prior to joining us, Ms. Church served in corporate counsel and compliance roles within the Merz Group of companies, most recently as Global Compliance Officer for Merz Pharma GmbH & Co KGaA, a privately-held pharmaceutical company, from March 2015 to August 2020. From June 1998 to December 2008, Ms. Church was Executive Vice President and General Counsel of Connetics Corporation, a specialty pharmaceutical company that was acquired by Stiefel Laboratories, Inc. in 2008. Ms. Church began her career as an attorney at Hopkins & Carley, a San Jose-based law firm. In 2020, Ms. Church was nominated for several industry awards for compliance training and received the 2020 Women in Compliance Award for “Most Impactful Compliance Training Programme of the Year” and the Brandon Hall 2020 Gold Medal for Excellence in Training. Ms. Church holds a Juris Doctor from New York University School of Law and a Bachelor of Arts in Comparative Literature from Duke University.

Corporate Governance

General

The Company's business and affairs are managed under the direction of its Board. The Board has adopted Corporate Governance Guidelines, a Code of Compliance and Ethics, and charters for its Audit and Risk Committee, Compensation Committee, Compliance, Ethics and Culture Committee and Nominating and Corporate Governance Committee to assist it in the exercise of its responsibilities and to serve as a framework for the effective governance of the Company. You can access the current Committee charters, Corporate Governance Guidelines, and Code of Compliance and Ethics in the “Documents and Charters” section under the “Corporate Governance” section of the “Investors” page of the Company's website located at www.bioventus.com, or by writing to the Secretary at the Company's offices at 4721 Emperor Blvd., Ste. 100, Durham, North Carolina 27703.

Board Composition

From the Company's initial public offering in 2021 until the 2024 Annual Meeting, the Board had been divided into three classes, each elected for a three-year term. At the 2024 Annual Meeting, the stockholders of the Company approved an amendment to the Company's charter to phase out the classified Board structure and provide for the annual election of directors commencing with this Annual Meeting.

Our Charter and Bylaws currently provide that, subject to the Stockholders Agreement, the authorized number of directors may be changed from time to time by the Board. Effective with the Annual Meeting and pursuant to Delaware law, the directors may be removed with or without cause by the affirmative vote of the holders of at least a majority of our outstanding voting stock entitled to vote in the election of directors.

BIOVENTUS • 2026 Proxy Statement 22

Table of Contents

Below is a matrix of the Board’s diversity as of April 22, 2026:


Board Diversity Matrix (as of April 22, 2026)
Total Number of Directors - 12 -
	Female	Male
Part I: Gender Identity
Directors	3	9
Part II: Demographic Background
African American or Black	1	0
White	2	8
Indian	0	1

CORPORATE GOVERNANCE

Director Independence

The Board undertook a review of the independence of the directors and considered whether any director has a material relationship with the Company that could compromise that director’s ability to exercise independent judgment in carrying out that director’s responsibilities. The Board has affirmatively determined that Mr. Bartholdson, Mr. Beyer, Dr. Dhankar, Mr. Hawkins, Mr. Cowdy, Ms. Ladone, Dr. McMurry-Heath, Mr. Neels, Mr. Nohra, Mr. Sutter, and Ms. Stalnecker are each an “independent director,” as defined under the rules of Nasdaq Stock Market LLC (the “Nasdaq Rules”). In making these determinations, the Board considered the current and prior relationships that each director has with our Company and all other facts and circumstances the Board deemed relevant in determining their independence, including the beneficial ownership of our Common Stock by each director, and the transactions involving them described in the section “Certain Relationships and Related Person Transactions” below.

Director Candidates

The Nominating and Corporate Governance Committee is primarily responsible for searching for qualified director candidates for election to the Board and filling vacancies on the Board. To facilitate the search process, the Nominating and Corporate Governance Committee may solicit current directors and executives of the Company for the names of potentially qualified candidates or ask directors and executives to pursue their own business contacts for the names of potentially qualified candidates. The Nominating and Corporate Governance Committee may also consult with outside advisors or retain search firms to assist in the search for qualified candidates, or consider director candidates recommended by our stockholders. Once potential candidates are identified, the Nominating and Corporate Governance Committee reviews the backgrounds of those candidates, evaluates candidates’ independence from the Company and potential conflicts of interest and determines if candidates meet the qualifications desired by the Nominating and Corporate Governance Committee for candidates for election as a director. Mr. Neels, Mr. Nohra, and Mr. Sutter were designated to serve on our Board by the Essex Stockholders. Mr. Cowdy and Dr. Dhankhar were designated to serve on the Board by the S+N Stockholders.

In evaluating the suitability of individual candidates (both new candidates and current Board members), the Nominating and Corporate Governance Committee, in recommending candidates for election, and the Board, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many factors, including: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly held company; strong finance experience; relevant social policy concerns; experience relevant to the Company’s industry; experience as a board member or executive officer of another publicly held company; relevant academic expertise or other proficiency in an area of the Company’s operations; diversity of expertise and experience in substantive matters pertaining to the Company’s business relative to other board members; diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience; practical and mature business judgment, including, but not limited to, the ability to make independent analytical inquiries; and any other relevant qualifications, attributes or skills. The Board evaluates each individual in the context of the Board as a whole, with the objective of assembling a group that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. In determining whether to recommend a director for re-election, the Nominating and Corporate Governance Committee may also consider the director’s past attendance at meetings and participation in and contributions to the activities of the Board.

BIOVENTUS • 2026 Proxy Statement 23

Table of Contents

Stockholders may recommend individuals to the Nominating and Corporate Governance Committee for consideration as potential director candidates by submitting the names of the recommended individuals, together with appropriate biographical information and background materials, to the Nominating and Corporate Governance Committee, c/o Secretary, Bioventus Inc., 4721 Emperor Blvd. Ste. 100, Durham, North Carolina 27703. In the event there is a vacancy, and assuming that appropriate biographical and background material has been provided on a timely basis, the Nominating and Corporate Governance Committee will evaluate stockholder-recommended candidates by following substantially the same process, and applying substantially the same criteria, as it follows for candidates submitted by others.

Communications from Stockholders

The Board will give appropriate attention to written communications that are submitted by stockholders and will respond if and as appropriate. Our Secretary is primarily responsible for monitoring communications from stockholders and for providing copies or summaries to the directors as he or she considers appropriate.

Communications are forwarded to the Board or individual directors, as applicable, if they relate to important substantive matters and include suggestions or comments that our Secretary and Chairperson of the Board consider to be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we tend to receive repetitive or duplicative communications. Stockholders who wish to send communications on any topic to the Board should address such communications to the Board in writing: c/o Secretary, Bioventus Inc., 4721 Emperor Blvd. Ste. 100, Durham, North Carolina 27703.

Board Leadership Structure and Role in Risk Oversight

The Board exercises its discretion in combining or separating the roles of Chairperson of the Board and Chief Executive Officer as it deems appropriate in light of prevailing circumstances. The Company believes that it, like many U.S. companies, is well-served by a flexible leadership structure. Currently, the roles are separated, with Mr. Hawkins serving as Chairperson of the Board (a position he has held since September 2020) and Mr. Claypoole serving as President and Chief Executive Officer. The Board has determined that separating the roles of Chairperson of the Board and Chief Executive Officer continues to be best for the Company and its stockholders because it allows Mr. Claypoole to focus on the day-to-day operation of the business and allows Mr. Hawkins to focus on Board-related matters. However, the Board will continue to consider whether the positions of Chairperson of the Board and Chief Executive Officer should be combined or separated at any given time as part of our succession planning process.

The Corporate Governance Guidelines provide that, if the Chairperson of the Board is a member of management or does not otherwise qualify as independent, the independent directors of the Board may elect a Lead Director whose responsibilities would include: presiding over all meetings of the Board at which the Chairperson is not present, including any executive sessions of the independent directors; approving Board meeting schedules and agendas; and acting as the liaison between the independent directors and the Chief Executive Officer and Chairperson of the Board. The Corporate Governance Guidelines further provide the flexibility for the Board to modify our leadership structure in the future as it deems appropriate. The Company currently does not have a Lead Director as the Chairperson qualifies as an independent director.

One of the key functions of the Board is informed oversight of the Company's risk management process. The Board has delegated to the Audit and Risk Committee oversight of the Company’s enterprise risk assessment and management processes, including oversight of the Company’s financial and cybersecurity risks. Management presents to the Audit and Risk Committee quarterly on cyber and information security. The Nominating and Corporate Governance Committee monitors the effectiveness of the Corporate Governance Guidelines. The Compensation Committee assesses and monitors whether any of the Company's compensation policies and programs has the potential to encourage excessive risk-taking. The Compliance, Ethics and Culture Committee is responsible for oversight of legal, compliance, and regulatory risks. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through committee reports about such risks.

BIOVENTUS • 2026 Proxy Statement 24

Table of Contents

Code of Compliance and Ethics

The Company has a written Code of Compliance and Ethics that applies to its directors, officers and employees, including the principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the Code is posted on the Company's website, www.bioventus.com under the “Corporate Governance” section of the “Investors” page. In addition, the Company intends to post on its website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the Code.

Anti-Hedging Policy and Insider Trading Compliance Policy

The Board has adopted an Insider Trading Compliance Policy, which applies to all of the directors, officers and employees (the “Insider Trading Policy”). The Insider Trading Policy prohibits directors, officers and employees and any entities they control from purchasing financial instruments such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s equity securities, or that may cause an officer, director, or employee to no longer have the same objectives as the Company’s other stockholders. The Insider Trading Policy applies whether such securities were granted as compensation or are otherwise held, directly or indirectly by the applicable individual or entity. Further, the Insider Trading Policy governs transactions in our securities by the Company, its directors, officers, employees, consultants and contractors, and is designed to ensure compliance with applicable insider trading laws, rules, and regulations. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 5, 2026.

Compensation Recovery Policy

In September 2023, the Board adopted the Bioventus, Inc. Compensation Recovery Policy (the “Compensation Recovery Policy”) to comply with the clawback rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act which added a new Section 10D to the Securities Exchange Act of 1934. The Compensation Recovery Policy requires the Company to seek the return, repayment, or forfeiture of any cash or equity-based incentive compensation payment or award made or granted to any current or former executive officer of the Company during the three completed fiscal years immediately preceding the date on which the Company is required to prepare a restatement of its financial statements due to material noncompliance of the Company with any financial reporting requirement under the federal securities laws (a “Restatement”), if: (i) the payment or award was granted, earned or vested based wholly or in part upon the attainment of a restated Company financial reporting measure (including, without limitation, company stock price, total shareholder return, global revenues, net income, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted global EBITDA, funds from operations, liquidity measures, returns measures and earnings measures); and (ii) a lower payment or award would have been made or granted to the executive officer based upon the restated financial results had there not been a Restatement. In each such instance, the amount required to be returned, repaid, or forfeited will be the amount by which the executive officer’s payment or award for the relevant period exceeded the lower payment or award that would have been made or granted based on the restated results (“Recoupment Amount”). The Recoupment Amount shall be computed without regard for any taxes paid and any recoupment pursuant to this Compensation Recovery Policy will be made on a “no fault” basis, without regard to whether any misconduct occurred or the executive may be deemed responsible for the noncompliance that resulted in the Restatement.

Attendance by Members of the Board of Directors at Meetings

There were four meetings of the Board during the fiscal year ended December 31, 2025. During the fiscal year ended December 31, 2025, each director attended at least 75% of the aggregate of (i) all meetings of the Board and (ii) all meetings of the committees on which the director served during the period in which he or she served as a director.

Under the Corporate Governance Guidelines, which are available on the Company's website at www.bioventus.com (in “Documents & Charters” under the “Corporate Governance” section of the “Investors” page), a director is expected to spend the time and effort necessary to properly discharge his or her responsibilities. Accordingly, a director is expected to regularly prepare for and attend meetings of the Board and all committees on which the director sits (including separate meetings of the independent directors), with the understanding that, on occasion, a director may be unable to attend a meeting. A director who is unable to attend a meeting of the Board or a committee of the Board is expected to notify the Chairperson of the Board or the Chairperson of the appropriate committee in advance of such meeting, and, whenever possible, participate in such meeting via teleconference in the case of an in-person meeting. We do not maintain a formal policy regarding director attendance at the Annual Meeting; however, we expect directors to attend, absent compelling circumstances. The majority of our then-current directors attended the 2025 Annual Meeting, namely Mr. Claypoole, Mr. Beyer, Mr. Cowdy Mr. Hawkins, Ms. Ladone, and Ms. Stalnecker.

BIOVENTUS • 2026 Proxy Statement 25

Table of Contents

Committees of the Board

The Board has established four standing committees: (1) Audit and Risk, (2) Compensation, (3) Compliance, Ethics and Culture and (4) Nominating and Corporate Governance—each of which operates under a written charter that has been approved by the Board.

The members of each of the Board committees and committee Chairpersons as of April 22, 2026, are set forth in the following chart.

Name

Audit and Risk

Compensation

Compliance, Ethics and Culture

Nominating and Corporate Governance

John A. Bartholdson

Chairperson

Patrick J. Beyer

Philip G. Cowdy

William A. Hawkins

Mary Kay Ladone

Michelle McMurry-Heath

Chairperson

Guido J. Neels

Guy P. Nohra

Susan M. Stalnecker

Chairperson

Martin P. Sutter

Chairperson

Audit and Risk Committee

The Board has a separately designated standing Audit and Risk Committee consisting of Patrick J. Beyer, Mary Kay Ladone and Susan M. Stalnecker, with Ms. Stalnecker serving as Chairperson. Each member of the Audit and Risk Committee meets the definition of “independent director” under the Nasdaq Rules, including those related to audit committee membership, and under Rule 10A-3 promulgated under the Exchange Act. In addition, the Board has determined that Ms. Stalnecker qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5)(ii) of Regulation S-K and that each member of the Audit and Risk Committee is able to read and understand fundamental financial statements.

Our Audit and Risk Committee’s responsibilities include:

•appointing, evaluating, approving the compensation of, and assessing the independence of our registered public accounting firm;

•overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm;

•reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;

•coordinating the Board’s oversight of the Company's internal control over financial reporting and disclosure controls and procedures;

•overseeing the Company’s enterprise risk assessment and management processes;

•overseeing the performance of the Company’s internal audit function;

•meeting independently with the Company's internal auditing staff, independent registered public accounting firm and management;

•reviewing and approving or ratifying any related person transactions;

•periodically reviewing our investment policy; and

•preparing the audit committee report required by the SEC rules (which is included on page 20 of this proxy statement).

The Audit and Risk Committee charter is available on the Company's website, located at www.bioventus.com, in “Documents and Charters” under the “Corporate Governance” section of the “Investors” page of the website.

The Audit and Risk Committee met six times in 2025.

BIOVENTUS • 2026 Proxy Statement 26

Table of Contents

Compensation Committee

The Compensation Committee is responsible for assisting the Board in the discharge of its responsibilities relating to the compensation of our executive officers. The members of the Compensation Committee are John A. Bartholdson, Mary Kay Ladone, and Guido J. Neels, with Mr. Bartholdson serving as Chairperson. Each person while serving as a member of the Compensation Committee qualifies as an independent director under Nasdaq’s heightened independence standards for members of a compensation committee and as a “non-employee director” as defined in Rule 16b-3 of the Exchange Act.

In fulfilling its purpose, the Compensation Committee has the following principal duties:

•reviewing and approving, or recommending for approval by the Board, the compensation of our Chief Executive Officer and our other executive officers;

•administration of the Company's Compensation Recovery Policy;

•overseeing and administering the Company's cash and equity incentive plans;

•reviewing and making recommendations to the Board with respect to director compensation;

•reviewing and discussing annually with management the Company's “Compensation Discussion and Analysis,” to the extent required;

•retaining or obtaining the advice of compensation consultants, counsel or other advisors as it deems necessary or appropriate to carry out its responsibilities;

•working with the Chief Executive Officer to evaluate succession plans for the Chief Executive Officer and other executive officers; and

•preparing the annual compensation committee report, to the extent required by SEC rules.

The Compensation Committee generally considers the Chief Executive Officer’s recommendations when making decisions regarding the compensation of executive officers (other than the Chief Executive Officer). Pursuant to the Compensation Committee’s charter, which is available on the Company's website at www.bioventus.com in “Documents and Charters” under the “Corporate Governance” section of the “Investors” page, the Compensation Committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. The Compensation Committee has engaged, Aon plc ("Aon") as executive compensation advisors to provide data to assist in making decisions regarding the amount and types of compensation to provide our executive officers and non-employee directors. As part of this process in 2025, the Compensation Committee reviewed a compensation assessment provided by Aon comparing our compensation to that of a group of peer companies within our industry and met with Aon to discuss our executive and non-employee director compensation and to receive input and advice. Aon reports directly to the Compensation Committee. The Compensation Committee has considered the adviser independence factors required under SEC rules as they relate to Aon and has determined that Aon's work does not raise a conflict of interest.

The Compensation Committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to time. The Compensation Committee may also delegate to an officer the authority to grant equity awards to certain employees, as further described in its charter and subject to the terms of our equity plans.

The Compensation Committee met five times during 2025.

Compliance, Ethics and Culture Committee

The Compliance, Ethics and Culture Committee’s responsibilities include:

•overseeing and maintaining an open line of communication with the Chief Compliance Officer, the Company's Senior Vice President, and General Counsel;

•reviewing, approving and overseeing the implementation of the annual Global Compliance Program; and

•overseeing the Company’s product quality management system.

The Compliance, Ethics and Culture Committee charter is available on the Company's website, www.bioventus.com, in “Documents and Charters” under the “Corporate Governance” section of the “Investors” page. The members of the Compliance, Ethics and Culture Committee are John A. Bartholdson, Michelle McMurry-Heath and Susan Stalnecker, with Dr. McMurry-Heath serving as Chairperson.

The Compliance, Ethics and Culture Committee met four times in 2025.

BIOVENTUS • 2026 Proxy Statement 27

Table of Contents

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee’s responsibilities include:

•identifying individuals qualified to become members of the Board;

•recommending to the Board the persons to be nominated for election as directors and to be appointed to each Board committee;

•retaining search firms as it deems necessary or appropriate;

•as relevant, recommending whether the Board should request the resignation of a director from the Board in accordance with the Company’s Corporate Governance Guidelines;

•reviewing and assessing the adequacy of the Company’s Corporate Governance Guidelines; and

•overseeing a periodic evaluation of the Board’s leadership structure and overseeing periodic self-evaluations of the Board.

The Nominating and Corporate Governance Committee charter is available on the Company's website, www.bioventus.com, in “Documents and Charters” under the “Corporate Governance” section of the “Investors” page. The members of the Nominating and Corporate Governance Committee are Philip G. Cowdy, William A. Hawkins, Guy P. Nohra, and Martin P. Sutter, with Mr. Sutter serving as Chairperson. The Nominating and Corporate Governance Committee has the authority to consult with outside advisors or retain search firms to assist in the search for qualified candidates or to consider director candidates recommended by the stockholders.

The Nominating and Corporate Governance Committee met twice in 2025.

Executive and Director Compensation

Executive Compensation

This section discusses the material components of the executive compensation program for the Company's executive officers who are named in the “2025 Summary Compensation Table” below. In 2025, the “named executive officers” of the Company and their positions were as follows:

•Robert E. Claypoole, President and Chief Executive Officer;

•Mark Singleton, Senior Vice President and Chief Financial Officer; and

•Anthony D’Adamio, Senior Vice President and General Counsel.

2025 Summary Compensation Table

The following table sets forth summary information concerning the compensation of our named executive officers for the years ended December 31, 2025 and 2024.


Name and Principal Position	Year	Salary ($)(1)		Bonus ($)(2)		Stock Awards ($)(3)		Option Awards ($)(3)		Non-Equity Incentive Plan Compensation ($)(4)		All Other Compensation ($)(5)		Total ($)
Robert E. Claypoole	2025	$	824,110	$	—	$	1,982,530	$	662,949	$	781,256	$	48,263	$	4,299,108
President & Chief Executive Officer	2024	780,328		750,000		1,833,750		1,785,850		1,198,584		30,498		6,379,010
Mark Singleton	2025	499,948		—		798,930		264,313		284,370		49,501		1,897,062
Senior Vice President & Chief Financial Officer	2024	473,825		50,000		669,325		434,750		436,677		23,099		2,087,676
Anthony D'Adamio	2025	469,350		—		523,010		173,320		222,472		21,837		1,409,989
Senior Vice President & General Counsel	2024	447,765		50,000		472,057		286,680		343,884		25,404		1,625,790

(1)Amounts reflect annual base salary earned with respect to 2025 and 2024 for Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio. See “Narrative to Summary Compensation Table—2025 Salaries” for further discussion of the base salary amounts.

(2)Amounts listed under the Bonus column include $750,000 paid to Mr. Claypoole as a hiring bonus in 2024 and $50,000 paid to Mr. Singleton and Mr. D’Adamio in 2024.

BIOVENTUS • 2026 Proxy Statement 28

Table of Contents

(3)Amounts reflect the aggregate grant date fair value of time-based RSUs, performance restricted stock units (“PRSUs”) or option awards computed in accordance with ASC Topic 718 for stock-based compensation transactions. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the RSUs or stock options, the performance conditions being met for the PRSUs, the exercise of the stock options, or the sale of the common stock underlying such RSUs, PRSUs or stock options. The reported grant date fair value of PRSUs is based on the probable outcome of the performance condition and assumes target performance goals will be achieved at 100%. For 2025, the grant date fair values of all PRSUs at maximum payout are $1,389,580, $559,980, and $373,320 for Messrs. Claypoole, Singleton and D’Adamio, respectively. See “Narrative to Summary Compensation Table—2021 Incentive Plan for further discussion of these awards.

(4)Amounts reflect the annual performance-based cash incentives earned by our named executive officers based on achievement of corporate performance objectives. See “Narrative to Summary Compensation Table—2025 Incentive Bonuses” for further discussion on how these amounts were determined.

(5)All other compensation consists of the following:


Name and Principal Position	Year	401(k) Match		Disability Insurance		Health Savings Account Company Contribution		Life Insurance		Executive Health Plan		Relocation		Other Personal Benefits			Total All Other Compensation
Robert E. Claypoole	2025	$	17,500	$	11,509	$	1,500	$	936	$	—	$	16,818	$	—		$	48,263
President & Chief Executive Officer	2024	17,249		10,964		1,385		900		—		—		—			30,498
Mark Singleton	2025	17,500		3,799		1,500		925		—		—		25,777		*	49,501
Senior Vice President & Chief Financial Officer	2024	17,250		3,463		1,500		886		—		—		—			23,099
Anthony D'Adamio	2025	17,500		3,459		—		878		—		—		—			21,837
Senior Vice President & General Counsel	2024	17,250		3,166		—		838		4,150		—		—			25,404

*Consists of the incremental costs to the Company for travel and accommodation related to Mr. Singleton's attendance at a Company sales recognition event.

Narrative to Summary Compensation Table

2025 Salaries

The named executive officers were entitled to receive a base salary in 2025 to compensate them for services rendered to the Company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the named executive officer’s skill set, experience, role and responsibilities. The annual base salaries payable to Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio as of December 31, 2025, were $832,000, $507,000, and $475,000, respectively.

See “Narrative to Summary Compensation Table—2024 Salaries” in our definitive proxy statement filed with the SEC on April 22, 2025, for a discussion of the base salaries as of December 31, 2024 for Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio.

2025 Incentive Bonuses

With respect to their services in 2025, Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio were eligible to earn an annual performance-based short-term incentive cash payment pursuant to the 2025 Global Annual Incentive Plan (the “AIP"). Bonuses eligible to be earned by our named executive officers under the AIP were based upon weighted minimum, target and maximum achievement of objective business performance measures. The AIP objective business performance measures in 2025 were (1) Global Revenue, (2) Adjusted Global EBITDA, (3) Quality, and (4) Cash Flow. Possible payouts for the objective business measures under the AIP ranged from 50% for minimum achievement, 100% for target achievement, to 200% for maximum achievement.

Mr. Claypoole’s target incentive for 2025 was 100% of his eligible earnings (as defined under the AIP), Mr. Singleton's was 60% of his eligible earnings, and Mr. D’Adamio's was 50% of his eligible earnings.

For 2025, the achievement percentage for the objective business performance measures for Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio was determined to be 94.8%.

See “Narrative to Summary Compensation Table—2024 Incentive Bonuses” in our definitive proxy statement filed with the SEC on April 22, 2025, for a discussion of the 2024 Incentive Bonuses for Mr. Singleton, and Mr. D’Adamio.

BIOVENTUS • 2026 Proxy Statement 29

Table of Contents

Equity-Based Compensation

2021 Incentive Plan

In connection with our IPO, the Board adopted (and our stockholders approved) the 2021 Incentive Plan in order to facilitate the grant of cash and equity incentives to the Company's non-employee directors, employees (including the named executive officers) and, as well as employees and consultants of the Company's subsidiaries and to enable the Company and its subsidiaries to obtain and retain the services of these individuals, which is essential to our long-term success.

During 2025, Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio received $662,949, $264,313 and $173,320 in options and $1,287,740, $518,940 and $336,350 in time-based RSUs under the 2021 Incentive Plan, respectively. In addition, Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio received $694,790, $279,990 and $186,660, respectively, in PRSUs (assuming target performance goals are met at 100%) under the 2021 Incentive Plan. The year ended December 31, 2025 was the first year in which the Company granted PRSUs. The PRSUs are subject to a 3-year cliff vesting period, contingent upon the achievement of a designated market condition at the end of the vesting term. The market condition is based on the Company’s relative total shareholder return (“TSR”). The fair value of the PRSUs was determined on the grant date using a Monte Carlo simulation model, which estimated TSR for the Company’s Class A common stock relative to a peer group consisting of companies included in the Russell 2000 Medical Equipment Index, along with additional selected companies. Actual shares issued in 2028 may range from 0% to 200% of the target award granted.

See “Narrative to Summary Compensation Table—Equity-Based Compensation—2021 Incentive Plan” in our definitive proxy statement filed with the SEC on April 22, 2025, for a discussion of the 2024 options and RSUs paid to Mr. Claypoole, Mr. Singleton, and Mr. D’Adamio.

2023 Retention Equity Award Plan

During year ended December 31, 2025 and 2024, no issuances were made under the 2023 Retention Plan.

2021 Employee Stock Purchase Plan

In connection with our IPO, we adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), in which all of our employees, including our named executive officers, who satisfy certain eligibility requirements may participate. The 2021 ESPP is intended to be operated as a qualified plan under Section 423 of the Code, though due to our corporate structure this is not a qualified plan. None of the Named Executive Officers are participants in the 2021 ESPP. As of December 31, 2025, 15 offering periods had occurred under the 2021 ESPP.

Policies and Practices for Granting Certain Equity Awards

Our practices regarding the granting of equity awards are designed to ensure compliance with applicable securities laws and to maintain the integrity of our compensation program. The Compensation Committee is responsible for the timing and terms of equity awards to executives. The Compensation Committee reviews its policies and practices related to equity awards to ensure they are consistent with the general standards of corporate governance and continue to serve the best interests of the Company and its stockholders.

The Company typically grants annual equity awards, including stock options to executive officers in the spring of each year in conjunction with regular Board and Compensation Committee meetings. For newly hired executive officers, equity awards, including stock options, are typically granted within approximately one month following their hire date. The Compensation Committee does not take material non-public information ("MNPI") into account when determining the timing and terms of equity awards, including stock options, and the Company does not time the disclosure of MNPI for the purpose of affecting the value of executive compensation.

Executive Compensation Arrangements

Employment Agreements

We entered into an employment agreement with Mr. Claypoole, our President and Chief Executive Officer and member of our Board, as of January 10, 2024. We entered into an employment agreement with Mr. Singleton, our Senior Vice President and Chief Financial Officer, effective as March 21, 2022. In connection with our IPO, we entered into a new employment agreement with Mr. D’Adamio, our Senior Vice President and General Counsel, effective as of February 11, 2021.

BIOVENTUS • 2026 Proxy Statement 30

Table of Contents

Severance

Under the employment agreements with Mr. Claypoole, Mr. Singleton and Mr. D’Adamio, upon a termination without cause or resignation by the named executive officer with good reason, each of our named executive officers are entitled to (i) 12 months’ base salary (18 months in the case of Mr. Claypoole), payable in equal installments over the 12 month period (18 month period in the case of Mr. Claypoole) following such termination, (ii) 100% of target annual cash incentive (150% in the case of Mr. Claypoole),payable in equal installments over the 12 month period (18 month period in the case of Mr. Claypoole) following such termination, and (iii) payment of COBRA premiums for the first 12 months of coverage following termination of employment (18 months in the case of Mr. Claypoole). Additionally, upon a termination without cause or resignation by the named executive officer with good reason within the 24 month period following a change in control, each of our named executive officers are entitled to (i) 18 months’ base salary (24 months in the case of Mr. Claypoole), payable in a lump sum within 60 days following such termination, (ii) 150% of target annual cash incentive (200% in the case of Mr. Claypoole) payable in a lump sum within 60 days following such termination, (iii) a lump sum payment equal to 18 months (24 months in the case of Mr. Claypoole) of COBRA premiums within 60 days following such termination, and (iv) full vesting acceleration of all equity awards. These severance payments will be conditioned upon execution and delivery of a release and compliance with the restrictive covenants described below in “—Restrictive Covenants.”

Restrictive Covenants

In connection with their respective employment agreements, the Company entered into post-employment restrictive covenants , including 12 month non-competition and non-solicitation obligations (extended to 18 months in the event a named executive officer receives change in control severance, as described above) and perpetual confidentiality and non-disparagement obligations.

Other Elements of Compensation

Retirement Plans

The Company currently maintains a 401(k) retirement savings plan (the "401(k) Plan") in which all of its employees who satisfy certain eligibility requirements may participate, including the named executive officers. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax and post-tax basis through contributions to the 401(k) Plan. Under the terms of the 401(k) Plan, the Company currently makes non-discretionary matching contributions equal to 100% of the first four percent and 50% of the next two percent of the employee’s eligible compensation. Further, the Board has discretion under the 401(k) Plan to provide for (i) discretionary matching contributions based on eligible compensation contributed by each employee and (ii) discretionary non-elective contributions in an amount determined by the Board at year end, subject to continued employment through year end. These discretionary plan provisions were not in use for 2025 or 2024. We believe that providing a vehicle for tax-deferred retirement savings though the 401(k) Plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including the named executive officers, in accordance with the Company's compensation policies. We anticipate that our employees will continue to be eligible to participate in a 401(k) Plan maintained by us.

Employee Benefits

All of the Company's full-time employees and working partners, including the named executive officers, are eligible to participate in health and welfare plans maintained by us, including:

•medical, dental and vision benefits;

•medical flexible spending accounts and health savings account;

•short-term and long-term disability insurance;

•basic life and accidental death & dismemberment insurance; and

•group accident, critical illness and hospital indemnity plans.

The named executive officers participate in these plans on the same basis as other eligible employees. The Company does not maintain any supplemental health and welfare plans for our named executive officers, other than for the most senior executives who have an opportunity to participate in an executive physical, beginning in 2025. The Company reimbursed the named executive officers for the full cost of their personal cellular phones. The Company believes the benefits described above are necessary and appropriate to provide a competitive compensation package to the named executive officers.

BIOVENTUS • 2026 Proxy Statement 31

Table of Contents

Section 280G

The employment agreements the Company entered into with the named executive officers, provide that in the case of their receipt of any payments in connection with a change in control (as defined in the employment letter or agreement), or that would otherwise be considered an “excess parachute payment” within the meaning of Section 280G of the Code, such payments will be reduced to the maximum amount that does not trigger the excise tax imposed by Section 4999 of the Code if the named executive officer would be better off on a net after-tax basis with such reduction.

Outstanding Equity Awards at 2025 Fiscal Year End

The following table summarizes the number of outstanding options, RSUs, and PRSUs for our named executive officers as of December 31, 2025. For additional information about the outstanding equity awards granted to our named executive officers, please see the sections titled “Equity-Based Compensation” and "Severance" above.


		Option Awards				Stock Awards
Name	Grant Date	Number of securities underlying unexercised options (#) exercisable	Number of securities underlying unexercised options (#) unexercisable	Option Exercise Price ($)	Option Expiration Date	Number of shares or units of stock that have not vested (#)	Market Value of shares or units that have not vested ($)		Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#)	Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($)
Robert E. Claypoole, Jr.	01/11/2024(1)	212,500	637,500	4.89	01/11/2034
Chief Executive Officer	01/11/2024(1)					281,250	2,092,500	(2)
	03/14/2025(3)	—	153,000	9.61	03/14/2035
	03/14/2025(3)					134,000	996,960	(2)
	03/14/2025(10)								67,000	498,480	(2)
Mark Singleton	04/04/2022(4)	167,400	55,800	13.29	04/03/2032
Senior Vice President & Chief Financial Officer	04/04/2022(4)					18,625	138,570	(2)
	04/10/2023(5)	67,900	67,900	1.16	04/10/2033
	04/10/2023(5)					26,000	193,440	(2)
	03/15/2024(6)	45,495	136,485	5.45	03/15/2034
	03/15/2024(6)					60,457	449,800	(2)
	03/14/2025(3)	—	61,000	9.61	03/14/2035
	03/14/2025(3)					54,000	401,760	(2)
	03/14/2025(10)								27,000	200,880	(2)
Anthony D'Adamio	02/11/2021(7)	168,100	—	13.00	02/10/2031
General Counsel	04/01/2021(8)	9,500	—	15.23	04/01/2031
	03/14/2022(9)	72,100	24,033	12.66	03/14/2032
	03/14/2022(9)					8,886	66,112	(2)
	04/10/2023(5)	51,800	51,800	1.16	04/10/2033
	04/10/2023(5)					19,850	147,684	(2)
	03/15/2024(6)	30,000	90,000	5.45	03/15/2034
	03/15/2024(6)					38,940	289,714	(2)
	03/14/2025(3)	—	40,000	9.61	03/14/2035
	03/14/2025(3)					35,000	260,400	(2)
	03/14/2025(10)								18,000	133,920	(2)

(1)The stock options and restricted stock units granted under the 2021 Incentive Plan vest in four approximately equal installments on each of the first four anniversaries of January 10, 2024.

(2)Amounts are calculated based on multiplying the number of shares shown in the table by the per share closing price of our Class A common stock on December 31, 2025 which was $7.44.

(3)The stock options and RSUs granted under the 2021 Incentive Plan vest in four approximately equal installments beginning on the first anniversary of March 15, 2025.

BIOVENTUS • 2026 Proxy Statement 32

Table of Contents

(4)The stock options and RSUs granted under the 2021 Incentive Plan vest in four approximately equal annual installments beginning on the first anniversary of March 21, 2022.

(5)The stock options and RSUs granted under the 2021 Incentive Plan vest in four approximately equal annual installments beginning on the first anniversary of April 10, 2023.

(6)The stock options and RSUs granted under the 2021 Incentive Plan vest in four approximately equal annual installments beginning on the first anniversary of February 15, 2024.

(7)The stock options granted under the 2021 Incentive Plan vest in four approximately equal annual installments beginning on the first anniversary of February 11, 2021.

(8)The stock options granted under the 2021 Incentive Plan vest in four approximately equal annual installments beginning on the first anniversary of April 1, 2021.

(9)The stock options and RSUs granted under the 2021 Incentive Plan vest in four approximately equal installments beginning on the first anniversary of March 14, 2022.

(10)Represents PRSUs granted in 2025 (assuming target performance goals are met at 100%), which are subject to a 3-year cliff vesting period, contingent upon the achievement of a designated market condition based on the Company’s relative TSR for the period from January 1, 2025 to December 31, 2027.at the end of the vesting term.

Director Compensation

The following table sets forth information concerning the compensation of the non-employee members of the Board for the year ended 2025.


Name	Stock Awards(1)		Fees Earned or Paid in Cash(2)		Total
William A. Hawkins	$	264,995	$	115,000	$	379,995
John Bartholdson	214,998		75,000		289,998
Patrick Beyer	214,998		67,500		282,498
Philip Cowdy	214,998		30,000		244,998
Ajay Dhankhar(3)	—		—		—
Mary Kay Ladone	214,998		75,000		289,998
Michelle McMurry-Heath	214,998		65,000		279,998
Guido J. Neels	214,998		62,500		277,498
Guy P. Nohra	214,998		60,000		274,998
Susan M. Stalnecker	214,998		85,000		299,998
Martin P. Sutter(4)	214,998		—		214,998

(1)Amounts reflect the aggregate grant-date fair value of the RSUs granted during 2025 computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in Note 7. Equity-Based Compensation to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. These amounts do not reflect the actual economic value that will be realized by the non-employee director upon the vesting of the RSUs or the sale of the common stock underlying such RSUs.

(2)Amounts reflect fees paid in accordance with the Company's non-employee director compensation policy in effect in 2025, which is described in further detail below.

(3)Dr. Dhankhar is an employee of Smith & Nephew and, as a result, does not receive compensation for his service on the Board.

(4)Mr. Sutter has waived cash compensation from Bioventus due to his position with EW Healthcare Partners.

BIOVENTUS • 2026 Proxy Statement 33

Table of Contents

For each non-employee director of the Board, the aggregate number of stock awards and options outstanding as of December 31, 2025 is set forth in the following table.


Name	Stock Awards Outstanding (Shares)	Stock Awards Outstanding (Options)
William A. Hawkins(1)	39,789	—
John A. Bartholdson(1)	32,282	—
Patrick Beyer(1)	32,282	34,906
Philip Cowdy(1)	32,282	—
Ajay Dhankhar	—
Mary Kay Ladone(1)	32,282	—
Michelle McMurry-Heath(1)	32,282	—
Guido J. Neels(1)	32,282	—
Guy P. Nohra(1)	32,282	—
Susan M. Stalnecker(1)	32,282	—
Martin P. Sutter(1)	32,282	—

(1)Amount consists of 32,282 RSUs granted on June 3, 2025 which vest on June 3, 2026 (or immediately prior to the date of the Annual Meeting, if sooner), subject to the Board member’s continued service through the applicable vesting date. As non-executive Chairperson of the Board, Mr. Hawkins' award was 39,789 shares. These awards are described in the Non-Employee Director Compensation Policy.

Non-Employee Director Compensation Policy

The Company's non-employee director compensation policy, which became effective February 11, 2021 and has been subsequently amended, currently provides that each non-employee director receives an annual cash retainer of $55,000. In addition, (i) the Chairperson of the Board receives an additional annual retainer of $55,000, (ii) the Lead Director of the Board receives an additional annual retainer of $30,000, (iii) the Chairpersons of the Audit and Risk Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Compliance, Ethics and Culture Committee receive additional annual retainers of $25,000 ($20,000 in 2024), $15,000, $10,000 and $10,000, respectively, and (iv) the non-Chairperson members of the Audit and Risk Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Compliance, Ethics and Culture Committee receive additional annual retainers of $12,500 ($10,000 in 2024), $7,500, $5,000 and $5,000, respectively. In addition, each such non-employee director receives an annual RSU award with a grant date value of $215,000 ($173,000 in 2024), and commencing in 2025, the Chairperson of the Board received an additional annual grant value of $50,000, with all such annual RSU awards (other than those received in respect of a non-employee director’s initial year of service, as described below) vesting on the first anniversary of the grant date of the award (or immediately prior to the date of the annual shareholder meeting immediately following the date of grant, if sooner), subject to such non-employee director continuing in service through such date. RSU awards for each non-employee director’s initial year of service vest in three equal installments, with the first installment vesting on the first anniversary of the grant date of such initial award (or immediately prior to the date of the annual shareholder meeting immediately following the date of grant, if sooner) and the second and third installments vesting on the first and second anniversaries of such first vesting date, subject to such non-employee director continuing in service through each such date (and any such nonemployee director who commences service on a date other than the date of the annual shareholder meeting receives a pro-rata RSU award for such initial year of service). Each RSU award awarded under the policy accelerates and vests in full upon a change in control (as defined in the 2021 Incentive Plan). In addition, each non-employee director is reimbursed for out-of-pocket expenses in connection with his or her services.

Security Ownership of Certain Beneficial Owners and Management

The following table presents information as to the beneficial ownership of our Class A common stock and Class B Common Stock, as of April 6, 2026 for:

•each person, or group of affiliated persons, known by us to beneficially own more than 5% of our Class A common stock or our Class B common stock;

•each named executive officer;

•each of the Company's directors; and

•all executive officers and directors as a group.

BIOVENTUS • 2026 Proxy Statement 34

Table of Contents

Smith & Nephew Inc. (the “Continuing LLC Owner”) is entitled to have its LLC Interests (as defined below) redeemed for Class A common stock on a one-for-one basis, or, if we and the Continuing LLC Owner agree, a cash payment equal to the market value of the applicable number of our shares of Class A common stock. In addition, at Bioventus’s election, Bioventus may effect a direct exchange of such Class A common stock or such cash (if mutually agreed) for such LLC Interests in lieu of such a redemption. In connection with its IPO, the Company issued to the Continuing LLC Owner one share of Class B common stock for each LLC Interest it owns. As a result, the number of shares of Class B common stock listed in the table below correlates to the number of LLC Interests the Continuing LLC Owner owns.

The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC and includes voting or investment power with respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of Common Stock subject to options, or other rights, including the redemption right described above, held by such person that are currently exercisable or will become exercisable within 60 days of April 6, 2026, are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each of the individuals and entities named below is c/o Bioventus Inc., 4721 Emperor Boulevard, Ste. 100, Durham, NC 27703. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.


	Shares of Class A Common Stock Beneficially Owned			Shares of Class B Common Stock Beneficially Owned		Combined Voting Power(1)
Name of Beneficial Owner	Number	%		Number	%	%
5% Stockholders
EW Healthcare Partners(2)	13,021,324	19.3	%	—	—	15.6	%
Juniper Investment Company, LLC(3)	6,939,357	10.3	%	—	—	8.3	%
Smith & Nephew(4)	6,229,991	9.2	%	15,786,737	100%	26.4	%
Nantahala Capital Management, LLC(5)	6,047,403	8.9	%	—	—	7.2	%
Named Executive Officers and Directors
Martin P. Sutter(2)(6)	13,138,847	19.4	%	—	—	15.7	%
John A. Bartholdson(3)(7)	7,051,259	10.4	%	—	—	8.5	%
Mark Singleton(8)	614,271	*		—	—	*
Robert E. Claypoole(9)	607,432	*		—	—	*
Anthony D'Adamio(10)	569,900	*		—	—	*
William A. Hawkins(11)	297,640	*		—	—	*
Guy P. Nohra(12)	148,892	*		—	—	*
Patrick Beyer(13)	143,624	*		—	—	*
Susan M. Stalnecker(14)	138,239	*		—	—	*
Guido J. Neels(15)	117,523	*		—	—	*
Mary Kay Ladone(16)	111,263	*		—	—	*
Michelle McMurry-Heath(17)	77,279	*		—	—	*
Philip G. Cowdy(18)	32,282	*		—	—	*
Ajay Dhankar	—	*		—	—	*
All current directors and executive officers as a group (15 persons)(19)	23,333,422	33.5	%	—	—	27.3	%

*Represents beneficial ownership of less than 1%.

(1)Represents the voting power of each owner based on the voting power held through both the owner’s Class A common stock and Class B common stock deemed to be beneficially owned. Represents percentage of voting power of the Class A common stock, based upon 67,638,295 shares of Bioventus Class A common stock outstanding, and Class B common stock, based upon 15,786,737 shares of Bioventus Class B common stock outstanding on April 6, 2026, voting together as a single class. To our knowledge, except as noted above, no person or entity is the beneficial owner of more than 5% of our Class A common stock or our Class B common stock.

BIOVENTUS • 2026 Proxy Statement 35

Table of Contents

(2)Based on a Schedule 13G/A filed with the SEC on January 22, 2024 and subsequent Form 4 filed by Martin P. Sutter on June 4, 2025. Represents 12,096,702 shares of Class A common stock held by EW Healthcare Partners Acquisition Fund, L.P. (the “Essex Stockholder”) and 924,622 shares of Class A common stock held by White Pine Medical, LLC, a subsidiary of the Essex Stockholder (“White Pine”). EW Healthcare Partners Acquisition Fund GP, L.P. (“Essex Stockholder GP”), the general partner of Essex Stockholder, and EW Healthcare Partners Acquisition Fund UGP, LLC, the general partner of Essex Stockholder GP ("EW Healthcare UGP"), have sole voting and dispositive power with respect to 13,021,324 shares of Class A common stock. Each of Mr. Sutter, Petri Vainio, Ron Eastman, and R. Scott Barry have shared voting and dispositive power with respect to the 13,021,324 shares of Class A common stock and disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of the Essex Stockholder, White Pine, Essex Stockholder GP, EW Healthcare UGP, and Messrs. Sutter, Vainio, Eastman and Barry is 21 Waterway Avenue, Suite 225, The Woodlands, Texas 77380.

(3)Based on a Schedule 13D/A filed with the SEC on June 16, 2023 and subsequent Form 4 filed August 20, 2024. Represents 6,939,357 shares of Class A common stock with deemed beneficial ownership as follows: Juniper Targeted Opportunity Fund, L.P. (“Juniper Fund”) beneficially owned 4,624,431 shares, Juniper Targeted Opportunities, L.P. (“Juniper Targeted Opportunities”) beneficially owned 2,239,076 shares and Juniper Multi-Strategy Fund, L.P. (“Juniper Multi-Strategy”) beneficial owned 75,850 shares. Juniper HF Investors II, LLC (“Juniper HF II”) is the general partner of Juniper Fund; Juniper Targeted Opportunity Investors, LLC (“Juniper TO”) is the general partner of Juniper Targeted Opportunities; and Juniper HF Investors, LLC (“Juniper HF”) is the general partner of Juniper Multi-Strategy. Juniper Investment Company, LLC (“Juniper Investment Company”) provides investment advisory and management services and is the investment advisor to Juniper Fund, Juniper Targeted Opportunities and Juniper Multi-Strategy. Each of Alexis P. Michas and John A. Bartholdson is a managing member of Juniper Investment Company. Each of Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy has the sole power to vote or direct their respective vote of 4,624,431, 2,239,076 and 75,850 shares and the sole power to dispose or direct the disposition of such shares. Juniper HF II, Juniper TO, Juniper HF, Juniper Investment Company and each of Messrs. Michas and Bartholdson may be deemed to share with Juniper Fund, Juniper Targeted Opportunities, and Juniper Multi-Strategy, as applicable, the power to vote or to direct the vote and to dispose or to direct the disposition of such shares. Messrs. Michas and Bartholdson each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of the foregoing reporting persons is 555 Madison Avenue, 24th Floor, New York, New York 10022.

(4)Based on a Schedule 13G filed with the SEC on February 7, 2022. Represents 6,229,991 shares of Class A common stock held by Smith & Nephew USD Limited (“SNUSD”) and 15,786,737 shares of Class B common stock held by Smith & Nephew, Inc. (“SNI”). Smith & Nephew plc (“S&N”) is the parent entity of SNUSD, and SNUSD is the parent entity of SNI. SNI also holds 15,786,737 common units of Bioventus LLC which are redeemable for shares of Class A common stock. Upon any such redemption and issuance, a corresponding number of shares of Class B common stock would be cancelled. Each of the foregoing reporting persons reports share voting and dispositive power with respect to the shares they report as beneficially owned. The address of S&N and SNUSD is Building 5, Croxley Park, Hatters Lane, Watford, Hertfordshire, WD18 8YE, UK. The address of SNI is 1450 E. Brooks Road, Memphis, Tennessee 38116.

(5)Based on a Schedule 13G/A filed with the SEC on February 13, 2026. Represents 6,047,403 shares of Class A common stock held of record by Nantahala Capital Management, LLC (“Nantahala”). Wilmot B. Harkey and Daniel Mack are the managing members of Nantahala and may each be deemed the beneficial owner of the shares held by Nantahala, and the control persons with respect to the shares owned by Nantahala, an investment advisor, who hold the shares by funds and separately managed accounts under its control. The foregoing reporting persons have shared voting and dispositive power with respect to such shares. The address of the foregoing reporting persons is 130 Main Street, 2nd Floor, New Canaan, Connecticut 06840.

(6)Consists of 12,096,702 shares of Class A common stock held by Essex Stockholder (see footnote (2)), 924,622 shares of Class A common stock held by White Pine (see footnote (2)), 85,241 shares of Class A common stock held directly by Mr. Sutter, and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(7)Consists of 4,624,431 shares of Class A common stock held by Juniper Fund (see footnote (3)), 2,239,076 shares of Class A common stock held by Juniper Targeted Opportunities (see footnote (3)), 75,850 shares of Class A common stock held by Juniper Multi-Strategy (see footnote (3)), 79,620 shares held directly by Mr. Bartholdson, and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(8)Consists of 169,981 shares of Class A common stock, 13,000 RSUs that may vest within 60 days of April 6, 2026 and 431,290 shares of Class A common stock issuable upon the exercise of options that either are vested or that may vest within 60 days of April 6, 2026.

(9)Consists of 135,944 shares of Class A common stock and 471,488 shares of Class A common stock issuable upon the exercise of options that either are vested or that may vest within 60 days of April 6, 2026.

(10)Consists of 148,042 shares of Class A common stock, 9,925 RSUs that may vest within 60 days of April 6, 2026, and 411,933 shares of Class A common stock issuable upon the exercise of options that either are vested or that may vest within 60 days of April 6, 2026.

(11)Consists of 257,851 shares of Class A common stock and 39,789 RSUs that may vest within 60 days of April 6, 2026.

(12)Consists of 116,610 shares of Class A common stock and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(13)Consists of 76,436 shares of Class A common stock, 32,282 RSUs that may vest within 60 days of April 6, 2026, and 34,906 shares of Class A common stock issuable upon the exercise of options that either are vested or that may vest within 60 days of April 6, 2026.

(14)Consists of 105,957 shares of Class A common stock and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(15)Consists of 85,241 shares of Class A common stock and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(16)Consists of 78,981 shares of Class A common stock and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(17)Consists of 44,997 shares of Class A common stock and 32,282 RSUs that may vest within 60 days of April 6, 2026.

(18)Consists of 32,282 RSUs that may vest within 60 days of April 6, 2026.

(19)Consists of 21,399,468 shares of Class A common stock, 357,552 RSUs that may vest within 60 days of April 6, 2026, and 1,576,402 shares of Class A common stock issuable upon the exercise of options that either are vested or that may vest within 60 days of April 6, 2026.

BIOVENTUS • 2026 Proxy Statement 36

Table of Contents

Certain Relationships and Related Person Transactions

Policies and Procedures for Related Person Transactions

The Board has adopted a written Related Party Transaction Policy, which sets forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we (or any of our subsidiaries) were to be a participant, where the amount involved exceeds $120,000 since the beginning of the prior fiscal year and a related person had, has or will have a direct or indirect material interest.

Under the policy, the Company's legal team is primarily responsible for developing and implementing procedures to obtain information regarding related persons and with respect to potential related person transactions, and then determining, based on the facts and circumstances, whether such transactions constitute related person transactions subject to the policy. The Company's General Counsel or his or her designee is then required to present to the Audit and Risk Committee each proposed related person transaction. In reviewing and approving any such transactions, the Audit and Risk Committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction.

If advance Audit and Risk Committee approval of a related person transaction is not feasible, then the transaction may be preliminarily entered into by management upon prior approval by the Chairperson of the Audit and Risk Committee, subject to ratification of the transaction by the Audit and Risk Committee at such committee’s next regularly scheduled meeting. Management is responsible for updating the Audit and Risk Committee as to any material changes to any approved or ratified related person transaction and for providing a status report at least annually of all then current related person transactions at a regularly scheduled meeting of the Audit and Risk Committee. No director may participate in approval of a related person transaction for which he or she is a related person. Unless noted otherwise, all of the transactions, agreements or relationships described in this section occurred prior to the adoption of this policy.

Since January 1, 2024, we engaged in certain transactions for which the amount involved exceeds $120,000 with our directors, executive officers or beneficial holders of more than 5% of our Common Stock, or immediate family member thereof. The following are summaries of certain provisions of our agreements with related persons and are qualified in their entirety by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable agreements, they do not necessarily contain all of the information that you may find useful. We therefore urge you to review the agreements in their entirety. Copies of the agreements (or forms of the agreements) are included as exhibits to our Annual Report on Form 10-K, for the year ended December 31, 2025 and are available electronically on the website of the SEC at www.sec.gov.

Our IPO and Transactions

In connection with our IPO, the Company engaged in certain transactions with certain of its directors, executive officers and other persons and entities that are or became holders of 5% or more of our voting securities upon the consummation of the IPO and including, without limitation (a) the amendment and restatement of the limited liability company agreement of BV LLC (the “Bioventus LLC Agreement”) entered into by the Company and Smith & Nephew Inc. (the “Continuing LLC Owner”) to, among other things, (i) provide for a new single class of common membership interests in BV LLC (the “LLC Interests”), (ii) exchange all of the then existing membership interests of the holders of BV LLC membership interests (the “Original LLC Owners”) for LLC Interests and (iii) appoint Bioventus Inc. as the sole managing member of BV LLC; (b) the acquisition, by various mergers, of certain members of BV LLC prior to the IPO (the “Former LLC Owners”) for which we issued 31,838,589 shares of Class A common stock as merger consideration (the “IPO Merger”); (c) entry into a tax receivable agreement (the “TRA”) with the Continuing LLC Owner, the Stockholders Agreement and a registration rights agreement with the Original LLC Owners (the “Registration Rights Agreement”) and (d) the satisfaction of a $3.3 million cash entitlement of the Continuing LLC Owner, in respect of an equity participation right unit held by the Continuing LLC Owner.

BIOVENTUS • 2026 Proxy Statement 37

Table of Contents

The IPO Merger involved the exchange of the indirect ownership interest in LLC Interests held by Former LLC Owners and occurred as a result of various mergers, whereby, in each case, a newly formed subsidiary of Bioventus merged into an entity that holds LLC Interests (and of which the Former LLC Owners were owners) with each entity becoming a wholly owned subsidiary of Bioventus and the Former LLC Owners receiving Class A common stock. Each Former LLC Owner and/or one or more its affiliates has agreed, pursuant to their respective merger agreement, to indemnify the Company against all historic liabilities of the entity transferred in the applicable merger. Subsequent to these mergers, each such entity merged into Bioventus resulting in Bioventus owning directly the LLC Interests exchanged by the Former LLC Owners pursuant to the initial mergers. In connection with the IPO Merger, the aggregate fair value of the Class A common stock transferred to certain of the Former LLC Owners, including EW Healthcare Partners, Smith & Nephew (Europe) B.V., Spindletop Healthcare Capital L.P., Ampersand Capital, Pantheon Global Co-Investment Opportunities Fund L.P. and Alta Partners VIII, L.P., each beneficially owing 5% or more of our Class A common stock, was approximately $413.9 million.

Tax Receivable Agreement

We expect to obtain an increase in our share of the tax basis of the assets of BV LLC when the Continuing LLC Owner receives shares of our Class A common stock or, if we and the Continuing LLC Owner agree, cash in connection with an exercise of the Continuing LLC Owner’s right to have its LLC Interests redeemed by BV LLC or, at our election, directly exchanged (such basis increases, together with the basis increases resulting from certain distributions (or deemed distributions) from BV LLC, the “Basis Adjustments”). We intend to treat such redemptions or exchanges of LLC Interests as the direct purchase of LLC Interests by us from the Continuing LLC Owner for U.S. federal income and other applicable tax purposes, regardless of whether such LLC Interests are surrendered by the Continuing LLC Owner to BV LLC for redemption or sold to us upon the exercise of our election to acquire such LLC Interests directly. A Basis Adjustment may have the effect of reducing the amounts that we would otherwise pay in the future to various tax authorities. The Basis Adjustments may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets.

We entered into the TRA with the Continuing LLC Owner. The TRA provides for our payment to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that we actually realize, or in some circumstances are deemed to realize, as a result of any Basis Adjustments and certain other tax benefits arising from payments under the TRA. BV LLC has in effect an election under Section 754 of the Code effective for each taxable year in which a redemption or exchange (including deemed exchange) of LLC Interests for shares of our Class A common stock or cash occurs. These TRA payments are not conditioned upon any continued ownership interest in either BV LLC or us by the Continuing LLC Owner. The rights of the Continuing LLC Owner under the TRA are assignable to transferees of its LLC Interests (other than us as transferee pursuant to subsequent redemptions or exchanges of the transferred LLC Interests). We expect to benefit from the remaining 15% of tax benefits, if any, that we may actually realize.

The actual Basis Adjustments, as well as any amounts paid to the Continuing LLC Owner under the TRA, will vary depending on a number of factors, including:

•the timing of any subsequent redemptions or exchanges—for instance, the increase in any tax deductions will vary depending on the fair value, which may fluctuate over time, of the depreciable or amortizable assets of BV LLC at the time of each redemption or exchange;

•the price of shares of our Class A common stock at the time of redemptions or exchanges—the Basis Adjustments, as well as any related increase in any tax deductions, is directly related to the price of shares of our Class A common stock at the time of each redemption or exchange;

•the extent to which such redemptions or exchanges are taxable—if a redemption or exchange is not taxable for any reason, increased tax deductions will not be available; and

•the amount and timing of our income—the TRA generally requires us to pay 85% of the tax benefits as and when those benefits are treated as realized under the terms of the TRA. Except as discussed below in cases of (i) a material breach of a material obligation under the TRA, (ii) a change of control or (iii) an early termination of the TRA, if we do not have taxable income, it will generally not be required to make payments under the TRA for that taxable year because no tax benefits will have been realized. However, any tax benefits that do not result in realized tax benefits in a given taxable year may generate tax attributes that may be utilized to generate tax benefits in future taxable years. The utilization of any such tax attributes will result in payments under the TRA.

BIOVENTUS • 2026 Proxy Statement 38

Table of Contents

For purposes of the TRA, cash savings in income tax will be computed by comparing our actual income tax liability to the amount of such taxes that it would have been required to pay had there been no Basis Adjustments and had the TRA not been entered into. The TRA generally applies to each of our taxable years, beginning with the first taxable year ending after the consummation of the offering. There is no maximum term for the TRA; however, the TRA may be terminated by us pursuant to an early termination procedure that requires us to pay the Continuing LLC Owner an agreed upon amount equal to the estimated present value of the remaining payments to be made under the agreement (calculated based on certain assumptions, including regarding tax rates and utilization of the Basis Adjustments).

The payment obligations under the TRA are our obligation and not BV LLC’s. Although the actual timing and amount of any payments that may be made under the TRA will vary, we expect that the payments that we may be required to make to the Continuing LLC Owner could be significant. Any payments made by us to the Continuing LLC Owner under the TRA generally reduces the amount of overall cash flow that might have otherwise been available to us or to BV LLC and, to the extent that we are unable to make payments under the TRA for any reason, the unpaid amounts generally are deferred and accrue interest until paid by the Company.

Decisions made by the Company in the course of running its business, such as with respect to mergers, asset sales, other forms of business combinations or other changes in control, may influence the timing and amount of payments that are received by the Continuing LLC Owner under the TRA. For example, the earlier disposition of assets following a transaction that results in a Basis Adjustment generally accelerate payments under the TRA and increase the present value of such payments.

The TRA provides that if (i) we materially breach any of our material obligations under the TRA, (ii) certain mergers, asset sales, other forms of business combination, or other changes of control were to occur, on or before December 31, 2021 or (iii) we elect an early termination of the TRA, then its obligations, or its successor’s obligations, under the TRA would be based on certain assumptions, including an assumption that we would have sufficient taxable income to fully utilize all potential future tax benefits that are subject to the TRA. The TRA also provides that in the case of certain mergers, asset sales, other forms of business combination or other changes of control occurring on or after December 31, 2021, payments under the TRA would be based on certain assumptions, including an assumption that in each taxable year ending on or after the change of control, we would have taxable income equal to the greater of (A) actual taxable income for such taxable year and (B) the product of (x) four and (y) the highest taxable income in any of the four fiscal quarters ended prior to the change in control (increased by 10% for each taxable year beginning with the second taxable year following the change in control), in each case, as adjusted to take into account our actual percentage ownership in BV LLC for the taxable year for which the tax benefit payment is being determined.

As a result of the foregoing, (i) we could be required to make cash payments to the Continuing LLC Owner that are greater than the specified percentage of the actual benefits we ultimately realize in respect of the tax benefits that are subject to the TRA, and (ii) if we materially breach any of our material obligations under the TRA or if we elected to terminate the TRA early, we would be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual realization, if any, of such future tax benefits. In these situations, our obligations under the TRA could have a material adverse effect on our liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combination, or other changes of control. There can be no assurance that we will be able to finance our obligations under the TRA. We anticipate funding ordinary course payments under the TRA from distributions from BV LLC out of distributable cash, to the extent permitted by our agreements governing our indebtedness.

BIOVENTUS • 2026 Proxy Statement 39

Table of Contents

Payments under the TRA are based on the tax reporting positions that we determine. Pursuant to the TRA, the Continuing LLC Owner is required to reimburse us for cash payments previously made to it pursuant to the TRA if any tax benefits actually realized by us are subsequently challenged by a taxing authority and ultimately disallowed. In addition, but without duplication of any amounts previously reimbursed by the Continuing LLC Owner, any excess cash payments made by us to the Continuing LLC Owner will be netted against any future cash payments that we might otherwise be required to make under the terms of the TRA. However, a challenge to any tax benefits actually realized by us may not arise for a number of years following the initial time of such payment and we might not determine that we have effectively made an excess cash payment to the Continuing LLC Owner for a number of years following the initial time of such payment. Moreover, there can be no assurance that any excess cash payments for which the Continuing LLC Owner has a reimbursement obligation under the TRA will be repaid to us. As a result, it is possible that we could make cash payments under the TRA that are substantially greater than our actual cash tax savings. The applicable U.S. federal income tax rules are complex and factual in nature, and we cannot assure you that the IRS or a court will not disagree with our tax reporting positions. We have full responsibility for, and sole discretion over, all of our and BV LLC’s tax matters, including the filing and amendment of all tax returns and claims for refund and defense of all tax contests, subject to certain participation and approval rights held by the Continuing LLC Owner.

Payments are generally due under the TRA within a specified period of time following the filing of our tax return for the taxable year with respect to which the payment obligation arises, although interest on such payments begin to accrue at a rate of LIBOR plus 100 basis points from the due date, without extensions, of such tax return and ending on the date that such payments are required to be made under the terms of the TRA. Any late payments that may be made under the TRA continue to accrue interest at LIBOR plus 500 basis points from the due date of such payments under the TRA until such payments are made, including any late payments that we may subsequently make because we did not have enough available cash to satisfy our payment obligations at the time at which they originally arose, including as a result of restrictions on payments to our equity owners in the agreements governing our indebtedness. There have been no payments to the Continuing LLC Owner made by the Company pursuant to this agreement since January 1, 2020.

Bioventus LLC Agreement

We operate our business through BV LLC and its subsidiaries. We and the Continuing LLC Owner entered into the Bioventus LLC Agreement, which sets forth terms for the operations of BV LLC, and the rights and obligations of the holders of LLC Interests.

Under the Bioventus LLC Agreement, we are a member and the sole manager of BV LLC. As the sole manager, we are able to control all of the day-to-day business affairs and decision-making of BV LLC. As such, we, through our officers and directors, are responsible for all operational and administrative decisions of BV LLC and the day-to-day management of BV LLC’s business. Pursuant to the terms of the Bioventus LLC Agreement, we cannot, under any circumstances, be removed as the sole manager of BV LLC except by our election.

We are not entitled to compensation for our services as manager. We are entitled to reimbursement or capital contribution credit by BV LLC for fees and expenses incurred on behalf of BV LLC, including all expenses associated with our IPO and maintaining our corporate existence.

The Bioventus LLC Agreement recapitalizes the units that were held prior to the IPO in BV LLC into a new single class of common membership units, which we refer to as the “LLC Interests.” Each LLC Interest entitles the holder to a pro rata share of the net profits and net losses and distributions of BV LLC.

BIOVENTUS • 2026 Proxy Statement 40

Table of Contents

The Bioventus LLC Agreement requires “tax distributions” to be made by BV LLC to its members, as that term is defined in the agreement. Tax distributions will be made to members on a pro rata basis, including us, in an amount sufficient to allow the members, including us, to pay taxes owed in respect of income allocated by BV LLC and to allow us to meet our obligations under the TRA (as described above under the heading “Tax Receivable Agreement” above). For tax distributions made in the fiscal year ending December 31, 2025 (the "2025 Fiscal Year"), the tax rate that we will use for purposes of determining tax distributions from BV LLC to its members will equal the combined federal, state, and local statutory tax rate applicable to us for the 2025 Fiscal Year, taking into account the deductibility of state and local taxes for federal purposes. For each subsequent fiscal year, the tax rate applicable to us for the 2025 Fiscal Year will apply with respect to tax distributions made during such fiscal year unless our Board determines otherwise. The tax rate used to determine tax distributions will apply regardless of the actual final tax liability of any such member. Tax distributions will also be made only to the extent all distributions from BV LLC for the relevant period were otherwise insufficient to enable each member to cover its tax liabilities as calculated in the manner described above. The Bioventus LLC Agreement allows for distributions to be made by BV LLC to its members on a pro rata basis out of “distributable cash,” as that term is defined in the agreement. We expect BV LLC may make distributions out of distributable cash periodically to the extent permitted by our agreements governing our indebtedness and necessary to enable us to cover our operating expenses and other obligations, including our tax liability and obligations under the TRA, as well as to make dividend payments, if any, to the holders of our Class A common stock.

The Bioventus LLC Agreement provides a redemption right to the Continuing LLC Owner which entitles it to have its LLC Interests redeemed, at its election, for newly-issued shares of our Class A common stock on a one-for-one basis or a cash payment equal to a volume weighted average market price of one share of Class A common stock for each LLC Interest redeemed (subject to customary adjustments, including for stock splits, stock dividends and reclassifications). If the Continuing LLC Owner elects to receive a cash payment, we may elect to settle such redemption with Class A common stock in lieu of a cash payment, provided that if we elect to do so, the Continuing LLC Owner has the option to rescind its redemption request within a specified time period. Upon the exercise of the redemption right, the redeeming member will surrender its LLC Interests to BV LLC for cancellation. The Bioventus LLC Agreement requires that we contribute cash or shares of our Class A common stock to BV LLC in exchange for an amount of newly-issued LLC Interests in BV LLC that will be issued to us equal to the number of LLC Interests redeemed from the Continuing LLC Owner. BV LLC will then distribute the cash or shares of our Class A common stock to the Continuing LLC Owner to complete the redemption. In the event of such a redemption election by the Continuing LLC Owner, we may effect a direct exchange of cash or Class A common stock for such LLC Interests in lieu of such a redemption. Whether by redemption or exchange, we are obligated to ensure that at all times the number of LLC Interests that we own equals the number of shares of Class A common stock issued by us (subject to certain exceptions for treasury shares and shares underlying certain convertible or exchangeable securities).

The Bioventus LLC Agreement provides for indemnification of the manager, members and officers of BV LLC and their respective subsidiaries or affiliates.

Stockholders Agreement

The Former LLC Owners and Continuing Owner, which hold Class A common stock or Class B common stock representing approximately 42.0% of the combined voting power of our Class A and Class B common stock as of April 6, 2026, entered into the Stockholders Agreement with us on February 16, 2021 (as amended, the "Stockholders Agreement").

Pursuant to the terms of the Stockholders Agreement, EW Healthcare Partners, Spindletop Healthcare Capital, Pantheon Global, Ampersand Capital, Alta Partners and their respective affiliates (the “Essex Members”), collectively have the right to designate up to three individuals to be included in the slate of nominees recommended by the Board. Smith & Nephew, Inc. and Smith & Nephew (Europe) B.V. (the “SN Members”), collectively have the right to designate up to two individuals to be included in the slate of nominees recommended by the Board. The number of individuals that the Essex Members and SN Members may designate decreases if they dispose of certain percentages of our Common Stock that they owned as of the date of the IPO. At such time as Essex owns less than 10% of the shares of Class A common stock, and SN Members owns less than 10% of the shares of Class A common stock and Class B common stock that they owned as of the date of the IPO (each, the "Ownership Threshold"), the Essex Members or SN Members, as the case may be, will no longer have designation rights under the Stockholders Agreement.

Additionally, under the Stockholders Agreement, any increase or decrease in the size of our Board or any committee, and any amendment to our organizational documents, in each case require the approval of the Essex and SN Members, for so long as each collectively own at least the Ownership Threshold.

BIOVENTUS • 2026 Proxy Statement 41

Table of Contents

Registration Rights Agreement

The Company entered into the Registration Rights Agreement with the Original LLC Owners on February 16, 2021 in connection with its IPO. The Registration Rights Agreement provides the Original LLC Owners certain registration rights whereby, the Continuing LLC Owner can require the Company to register under the Securities Act shares of Class A common stock issuable to it upon, at our election, redemption or exchange of its LLC Interests, and the Former LLC Owners can require us to register under the Securities Act the shares of Class A common stock issued to them in connection with certain transactions completed in connection with the IPO. The Registration Rights Agreement provides for piggyback registration rights for the Original LLC Owners.

On October 25, 2024, the Company filed a registration statement on Form S-3 to, in part, register for resale 35,038,052 shares of our Class A common stock held by the Selling Securityholders, of which 15,786,737 shares are issuable upon the exchange of their outstanding LLC Interests.

Indemnification Agreements

The Company has entered into separate indemnification agreements with its directors and executive officers. The indemnification agreements provide for indemnification of the directors and executive officers for expenses, judgments, fines and settlement amounts incurred by this person in any action or proceeding arising out of this person’s services as a director or executive officer or at the Company's request. There have been no payments made by the Company pursuant to these agreements since January 1, 2021.

BIOVENTUS • 2026 Proxy Statement 42

Table of Contents

Stockholders’ Proposals

Stockholders who intend to have a proposal considered for inclusion in our proxy materials for presentation at our 2027 Annual Meeting pursuant to Rule 14a-8 under the Exchange Act must submit the proposal to our Secretary at the Company's offices at 4721 Emperor Blvd. Ste. 100, Durham, North Carolina 27703 in writing not later than December 23, 2026. Stockholders intending to present a proposal at the 2027 Annual Meeting, but not to include the proposal in our proxy statement, or to nominate a person for election as a director, must comply with the requirements set forth in our Bylaws. Our Bylaws require, among other things, that our Secretary receive written notice from the stockholder of record of their intent to present such proposal or nomination not less than 90 days nor more than 120 days prior to the anniversary of the preceding year’s annual meeting. Therefore, we must receive notice of such a proposal or nomination for the 2027 Annual Meeting no later than March 5, 2027 and no earlier than February 3, 2027. The notice must contain the information required by the Bylaws, a copy of which is available upon request to our Secretary. The proxy holders named on the Company’s proxy card will have discretion to vote proxies given to them on any shareholder proposal of which our Company does not have notice prior to March 8, 2027.

In the event that the date of the 2027 Annual Meeting is more than 30 days before or more than 60 days after June 3, 2027, then our Secretary must receive such written notice not later than the close of business on the 90th day prior to the 2027 Annual Meeting or, if later, the close of business on 10th day following the day on which public disclosure of the date of such meeting is first made by us.

In addition to satisfying the foregoing requirements under our Bylaws, including the notice deadline set forth above, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees for the 2027 Annual Meeting must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act.

The Company reserves the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these or other applicable requirements.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our directors, officers (as defined under Rule 16a-1(f) under the Exchange Act) and stockholders who beneficially own more than 10% of any class of our equity securities registered pursuant to Section 12 of the Exchange Act (collectively, the “Reporting Persons”) to file initial statements of beneficial ownership of securities and statements of changes in beneficial ownership of securities with respect to our equity securities with the SEC. All Reporting Persons are required by SEC regulation to furnish us with copies of all reports that such Reporting Persons file with the SEC pursuant to Section 16(a). Based solely on our review of the copies of such forms received by us and upon written representations of the Reporting Persons received by us, we believe that there has been compliance with all Section 16(a) filing requirements applicable to such Reporting Persons with respect to the fiscal year ended December 31, 2025, with the exception of: Ms. Church and Messrs. Claypoole, D’Adamio and Singleton, who filed Forms 4 on March 17, 2026 reporting the acquisition of 16,000, 153,000, 40,000 and 61,000 shares underlying options, respectively, and 14,000, 134,000, 35,000 and 54,000 shares underlying restricted stock units, respectively, on March 14, 2025; Mr. Bartholdson, who filed a Form 4 on June 5, 2025 reporting the vesting of 26,493 RSUs on June 2, 2025; and Dr. Dhankhar, who filed a Form 3 on November 25, 2025 reporting the commencement of his relationship as a director of the Company on November 14, 2025.

Compensation Committee Interlocks and Insider Participation

During the fiscal year ended December 31, 2025, John A. Bartholdson, Guido J. Neels and Mary Kay Ladone served as members of the Compensation Committee. To our knowledge, during the fiscal year ended December 31, 2025, none of the relationships required to be disclosed by SEC rules existed aside from those identified herein. See “Certain Relationships and Related Person Transactions” for a description of the Stockholder Agreement and Registration Rights Agreement involving EW Healthcare Partners and Alta Partners.

BIOVENTUS • 2026 Proxy Statement 43

Table of Contents

Other Matters

The Board is not aware of any matter to be presented for action at the Annual Meeting other than the matters referred to above and does not intend to bring any other matters before the Annual Meeting. However, if other matters should come before the Annual Meeting, it is intended that holders of the proxies named on the Company’s proxy card will vote thereon in their discretion.

Solicitation of Proxies

The accompanying proxy is solicited by and on behalf of the Board, whose Notice of Annual Meeting is attached to this proxy statement, and the entire cost of our solicitation will be borne by the Company. In addition to the use of mail, proxies may be solicited by personal interview, telephone, e-mail and facsimile by our directors, officers and other employees who will not be specially compensated for these services. We will also request that brokers, nominees, custodians and other fiduciaries forward soliciting materials to the beneficial owners of shares held by the brokers, nominees, custodians and other fiduciaries. We will reimburse these persons for their reasonable expenses in connection with these activities.

We have filed this definitive proxy statement, including proxy card, with the SEC in connection with our solicitation of proxies for our Annual Meeting. Stockholders may obtain the definitive proxy statement (and any amendments and supplements thereto) and other documents as and when filed by Bioventus with the SEC without charge from the SEC’s website at: www.sec.gov.

Certain information contained in this statement relating to the occupations and security holdings of our directors and officers is based upon information received from the individual directors and officers.

BIOVENTUS • 2026 Proxy Statement 44

Table of Contents

Bioventus’s Annual Report on Form 10-K

A copy of Bioventus’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including financial statements and schedules thereto but not including exhibits, as filed with the SEC, will be sent to any stockholder of record on April 6, 2026 without charge upon written request addressed to:

Bioventus Inc.

Attention: Secretary

4721 Emperor Blvd. Ste. 100,

Durham, North Carolina 27703

A reasonable fee will be charged for copies of exhibits. You also may access the proxy statement and our Annual Report on Form 10-K at www.proxyvote.com. You also may access our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 at www.Bioventus.com.

WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING ONLINE, WE URGE YOU TO VOTE YOUR SHARES VIA THE TOLL-FREE TELEPHONE NUMBER OR OVER THE INTERNET, AS DESCRIBED IN THIS PROXY STATEMENT. IF YOU RECEIVED A COPY OF THE PROXY CARD BY MAIL, YOU MAY SIGN, DATE AND MAIL THE PROXY CARD IN THE ENCLOSED RETURN ENVELOPE. PROMPTLY VOTING YOUR SHARES WILL ENSURE THE PRESENCE OF A QUORUM AT THE ANNUAL MEETING AND WILL SAVE US THE EXPENSE OF FURTHER SOLICITATION.

By Order of the Board of Directors

Anthony D’Adamio

Senior Vice President, General Counsel and Secretary

Durham, North Carolina

April 22, 2026

BIOVENTUS • 2026 Proxy Statement 45

Table of Contents

BIOVENTUS INC.

4721 EMPEROR BOULEVARD, STE. 100

DURHAM, NORTH CAROLINA 27703

SEC Form DEF 14A filed by Bioventus Inc.